

WEBVTT

NOTE duration:"01:00:46"

NOTE recognizability:0.822

NOTE language:en-us

NOTE Confidence: 0.802374280588235

00:00:00.000 --> 00:00:01.716 So the yield Cancer Center I

NOTE Confidence: 0.802374280588235

00:00:01.716 --> 00:00:03.243 wanted to welcome those attending

NOTE Confidence: 0.802374280588235

00:00:03.243 --> 00:00:05.175 as well as my participants here

NOTE Confidence: 0.802374280588235

00:00:05.180 --> 00:00:07.958 for the ash update on lymphoma.

NOTE Confidence: 0.802374280588235

00:00:07.960 --> 00:00:09.952 So my name is Scott Harrington

NOTE Confidence: 0.802374280588235

00:00:09.952 --> 00:00:12.012 lymphoma clinician as well as a

NOTE Confidence: 0.802374280588235

00:00:12.012 --> 00:00:13.360 health services researcher and

NOTE Confidence: 0.802374280588235

00:00:13.360 --> 00:00:15.240 I'm joined with Doctor Kothari.

NOTE Confidence: 0.802374280588235

00:00:15.240 --> 00:00:17.778 He'll be focusing on aggressive B

NOTE Confidence: 0.802374280588235

00:00:17.778 --> 00:00:19.728 cell malignancies and mantle cell

NOTE Confidence: 0.802374280588235

00:00:19.728 --> 00:00:22.101 lymphoma as well as doctor Taxin Sethi

NOTE Confidence: 0.802374280588235

00:00:22.101 --> 00:00:24.268 who will present some updates on

NOTE Confidence: 0.802374280588235

00:00:24.268 --> 00:00:26.720 Hodgkin lymphoma and T cell lymphomas.

NOTE Confidence: 0.802374280588235

00:00:26.720 --> 00:00:28.232 Dr Frost will be joining us
NOTE Confidence: 0.802374280588235

00:00:28.232 --> 00:00:30.069 towards the end to help lead the.
NOTE Confidence: 0.802374280588235

00:00:30.070 --> 00:00:31.570 Question and answer discussion.
NOTE Confidence: 0.905562311111111

00:00:35.900 --> 00:00:38.126 So I know many have been focused
NOTE Confidence: 0.905562311111111

00:00:38.126 --> 00:00:40.288 on COVID and would love to
NOTE Confidence: 0.905562311111111

00:00:40.288 --> 00:00:42.183 look forward into the future.
NOTE Confidence: 0.905562311111111

00:00:42.190 --> 00:00:45.054 But in terms of indolent lymphomas and CLL,
NOTE Confidence: 0.905562311111111

00:00:45.060 --> 00:00:47.170 my slides are actually mostly
NOTE Confidence: 0.905562311111111

00:00:47.170 --> 00:00:50.058 focused on on how to kind of
NOTE Confidence: 0.905562311111111

00:00:50.058 --> 00:00:52.003 navigate our patients through the
NOTE Confidence: 0.905562311111111

00:00:52.003 --> 00:00:54.560 COVID era with indolent lymphomas.
NOTE Confidence: 0.905562311111111

00:00:54.560 --> 00:00:55.680 He's in my disclosures.
NOTE Confidence: 0.783083061111111

00:00:58.530 --> 00:01:00.545 And when we think about
NOTE Confidence: 0.783083061111111

00:01:00.545 --> 00:01:02.157 approaching sealant on how,
NOTE Confidence: 0.783083061111111

00:01:02.160 --> 00:01:03.840 given the uncertainty that we are
NOTE Confidence: 0.783083061111111

00:01:03.840 --> 00:01:05.470 facing with the COVID pandemic,

NOTE Confidence: 0.7830830611111111
00:01:05.470 --> 00:01:07.474 there's a few takeaways of historical
NOTE Confidence: 0.7830830611111111
00:01:07.474 --> 00:01:09.838 data that really come to forefront of
NOTE Confidence: 0.7830830611111111
00:01:09.838 --> 00:01:11.764 my mind when approaching a patient,
NOTE Confidence: 0.7830830611111111
00:01:11.770 --> 00:01:12.853 and that's that.
NOTE Confidence: 0.7830830611111111
00:01:12.853 --> 00:01:14.658 The improvement in progression free
NOTE Confidence: 0.7830830611111111
00:01:14.658 --> 00:01:16.262 survival infrequently has translated
NOTE Confidence: 0.7830830611111111
00:01:16.262 --> 00:01:18.332 to overall survival benefits for
NOTE Confidence: 0.7830830611111111
00:01:18.332 --> 00:01:20.156 patients receiving first line treatment
NOTE Confidence: 0.7830830611111111
00:01:20.156 --> 00:01:22.040 for in lymphomas very different from
NOTE Confidence: 0.7830830611111111
00:01:22.040 --> 00:01:23.902 my colleagues will be talking about
NOTE Confidence: 0.7830830611111111
00:01:23.902 --> 00:01:25.863 DLBCL and Ansel cell and Hodgkin,
NOTE Confidence: 0.7830830611111111
00:01:25.863 --> 00:01:29.567 but in this situation where CL and lymphoma.
NOTE Confidence: 0.7830830611111111
00:01:29.570 --> 00:01:32.852 This kind of association has been
NOTE Confidence: 0.7830830611111111
00:01:32.852 --> 00:01:34.998 seen frequently and there were some
NOTE Confidence: 0.7830830611111111
00:01:34.998 --> 00:01:36.570 updates showing out here at Ash.
NOTE Confidence: 0.7830830611111111

00:01:36.570 --> 00:01:38.466 This was doctor Wack who presented
NOTE Confidence: 0.7830830611111111

00:01:38.466 --> 00:01:41.032 the update on the Alliance study and
NOTE Confidence: 0.7830830611111111

00:01:41.032 --> 00:01:43.095 this was a randomized randomized
NOTE Confidence: 0.7830830611111111

00:01:43.095 --> 00:01:45.235 study comparing bendamustine rituximab
NOTE Confidence: 0.7830830611111111

00:01:45.235 --> 00:01:48.855 to a brute model therapy or brute
NOTE Confidence: 0.7830830611111111

00:01:48.855 --> 00:01:50.525 rituximab and this was an important
NOTE Confidence: 0.7830830611111111

00:01:50.525 --> 00:01:52.465 study that really led to the use of
NOTE Confidence: 0.7830830611111111

00:01:52.465 --> 00:01:54.254 front line of root nymph and many of
NOTE Confidence: 0.7830830611111111

00:01:54.254 --> 00:01:55.738 our patients and that was based off
NOTE Confidence: 0.7830830611111111

00:01:55.738 --> 00:01:57.726 of a really progression free survival
NOTE Confidence: 0.7830830611111111

00:01:57.726 --> 00:02:00.060 benefit both in the model therapy.
NOTE Confidence: 0.7830830611111111

00:02:00.060 --> 00:02:02.412 Farm as well as the route number toxin
NOTE Confidence: 0.7830830611111111

00:02:02.412 --> 00:02:04.655 that Barm both had a hazard ratio of
NOTE Confidence: 0.7830830611111111

00:02:04.660 --> 00:02:06.940 1.36 in the updated median follow-up
NOTE Confidence: 0.7830830611111111

00:02:06.940 --> 00:02:09.534 of 55 months that PFS benefit was
NOTE Confidence: 0.7830830611111111

00:02:09.534 --> 00:02:12.700 was made to be quite impressive.

NOTE Confidence: 0.7830830611111111
00:02:12.700 --> 00:02:14.891 Doctor William did a very nice job
NOTE Confidence: 0.7830830611111111
00:02:14.891 --> 00:02:17.520 in terms of presenting updated PFS
NOTE Confidence: 0.7830830611111111
00:02:17.520 --> 00:02:20.340 stratified by risk factors and CLL,
NOTE Confidence: 0.7830830611111111
00:02:20.340 --> 00:02:21.586 but she also had this slide here,
NOTE Confidence: 0.7830830611111111
00:02:21.590 --> 00:02:23.312 which was overall survival and so
NOTE Confidence: 0.7830830611111111
00:02:23.312 --> 00:02:25.190 at a median follow-up of 55 months.
NOTE Confidence: 0.7830830611111111
00:02:25.190 --> 00:02:26.895 Overall survival between the three
NOTE Confidence: 0.7830830611111111
00:02:26.895 --> 00:02:28.600 arms was that really identical
NOTE Confidence: 0.7830830611111111
00:02:28.653 --> 00:02:30.068 and it's important to note.
NOTE Confidence: 0.7830830611111111
00:02:30.070 --> 00:02:32.919 Got to follow up for this analysis
NOTE Confidence: 0.7830830611111111
00:02:32.919 --> 00:02:34.826 was locked at April 2020.
NOTE Confidence: 0.7830830611111111
00:02:34.826 --> 00:02:37.227 Kind of right before the pandemic and
NOTE Confidence: 0.7830830611111111
00:02:37.227 --> 00:02:39.708 so having both this data as well as
NOTE Confidence: 0.7830830611111111
00:02:39.708 --> 00:02:41.915 the corresponding ACOG study that was
NOTE Confidence: 0.7830830611111111
00:02:41.915 --> 00:02:44.646 FDR versus abroad number Tux map will be,
NOTE Confidence: 0.7830830611111111

00:02:44.646 --> 00:02:45.222 I think,
NOTE Confidence: 0.7830830611111111

00:02:45.222 --> 00:02:46.950 important in terms of overall survival
NOTE Confidence: 0.7830830611111111

00:02:47.010 --> 00:02:48.660 and how we address our patients.
NOTE Confidence: 0.7830830611111111

00:02:48.660 --> 00:02:49.940 When we think about indolent,
NOTE Confidence: 0.7830830611111111

00:02:49.940 --> 00:02:53.127 non Hodgkin lymphoma is often in
NOTE Confidence: 0.7830830611111111

00:02:53.127 --> 00:02:56.046 the use of maintenance is a hot
NOTE Confidence: 0.7830830611111111

00:02:56.046 --> 00:02:59.311 topic and this is just a little bit
NOTE Confidence: 0.7830830611111111

00:02:59.311 --> 00:03:01.693 dated data now of follicular pharma
NOTE Confidence: 0.7830830611111111

00:03:01.693 --> 00:03:03.370 maintenance or following our chemo.
NOTE Confidence: 0.7830830611111111

00:03:03.370 --> 00:03:05.890 This is a randomized study PRIMA study
NOTE Confidence: 0.7830830611111111

00:03:05.952 --> 00:03:08.202 and this is the data at 10 years and
NOTE Confidence: 0.7830830611111111

00:03:08.202 --> 00:03:10.240 what we see is that adding maintenance
NOTE Confidence: 0.7830830611111111

00:03:10.240 --> 00:03:12.415 rituximab for two years certainly
NOTE Confidence: 0.7830830611111111

00:03:12.415 --> 00:03:14.559 improves progression free survival type.
NOTE Confidence: 0.7830830611111111

00:03:14.560 --> 00:03:17.370 The next treatment time to
NOTE Confidence: 0.7830830611111111

00:03:17.370 --> 00:03:19.618 delay of cytotoxic chemotherapy.

NOTE Confidence: 0.7830830611111111
00:03:19.620 --> 00:03:21.496 In pretty stark differences,
NOTE Confidence: 0.7830830611111111
00:03:21.496 --> 00:03:24.540 10.5 years in median PFS compared to
NOTE Confidence: 0.7830830611111111
00:03:24.540 --> 00:03:26.400 4.1 for those without maintenance.
NOTE Confidence: 0.7830830611111111
00:03:26.400 --> 00:03:27.026 But again,
NOTE Confidence: 0.7830830611111111
00:03:27.026 --> 00:03:28.904 the overall survival in this patient
NOTE Confidence: 0.7830830611111111
00:03:28.904 --> 00:03:31.680 population at 9 years was identical.
NOTE Confidence: 0.7830830611111111
00:03:31.680 --> 00:03:33.220 So why do we think about that?
NOTE Confidence: 0.7830830611111111
00:03:33.220 --> 00:03:34.844 As we move forward,
NOTE Confidence: 0.7830830611111111
00:03:34.844 --> 00:03:36.874 is that our patients within
NOTE Confidence: 0.7830830611111111
00:03:36.874 --> 00:03:39.280 lymphomas usually live for for years,
NOTE Confidence: 0.7830830611111111
00:03:39.280 --> 00:03:40.780 often well over a decade,
NOTE Confidence: 0.7830830611111111
00:03:40.780 --> 00:03:43.144 and if there's a new potential
NOTE Confidence: 0.7830830611111111
00:03:43.144 --> 00:03:45.676 downside or new pandemic that might
NOTE Confidence: 0.7830830611111111
00:03:45.676 --> 00:03:47.876 impact their long term survival,
NOTE Confidence: 0.7830830611111111
00:03:47.880 --> 00:03:48.741 a focus of,
NOTE Confidence: 0.7830830611111111

00:03:48.741 --> 00:03:51.168 I think of our management needs to be
NOTE Confidence: 0.7830830611111111

00:03:51.168 --> 00:03:53.256 addressed in that in that situation,
NOTE Confidence: 0.7830830611111111

00:03:53.260 --> 00:03:56.148 and so most of the data on concerns
NOTE Confidence: 0.7830830611111111

00:03:56.148 --> 00:03:58.415 of differential impact on COVID in
NOTE Confidence: 0.7830830611111111

00:03:58.415 --> 00:04:00.623 our patients has been mostly data
NOTE Confidence: 0.889315382857143

00:04:00.697 --> 00:04:03.212 from CLO. This was very nice work from the
NOTE Confidence: 0.889315382857143

00:04:03.212 --> 00:04:04.939 French innovative leukemia organization.
NOTE Confidence: 0.889315382857143

00:04:04.940 --> 00:04:07.957 From Doctor Bacchus in and what they
NOTE Confidence: 0.889315382857143

00:04:07.957 --> 00:04:11.160 looked at was just over 500 patients
NOTE Confidence: 0.889315382857143

00:04:11.160 --> 00:04:14.335 treated in 17 French groups in with
NOTE Confidence: 0.889315382857143

00:04:14.335 --> 00:04:17.040 CLL and they presented the antibody
NOTE Confidence: 0.889315382857143

00:04:17.040 --> 00:04:20.656 response to two vaccines of M RNA COVID
NOTE Confidence: 0.889315382857143

00:04:20.656 --> 00:04:23.400 vaccinations and what we see is about
NOTE Confidence: 0.889315382857143

00:04:23.480 --> 00:04:25.995 70% of patients that were treatment
NOTE Confidence: 0.889315382857143

00:04:25.995 --> 00:04:28.270 naive mounted antibody response compared
NOTE Confidence: 0.889315382857143

00:04:28.340 --> 00:04:30.580 to 60% that were treated prior but off

NOTE Confidence: 0.889315382857143
00:04:30.580 --> 00:04:33.168 therapy at the time of their vaccination.
NOTE Confidence: 0.889315382857143
00:04:33.170 --> 00:04:34.940 And that compared pretty favorable
NOTE Confidence: 0.889315382857143
00:04:34.940 --> 00:04:36.710 compared to the on treatments.
NOTE Confidence: 0.889315382857143
00:04:36.710 --> 00:04:40.040 Only 22% of patients that received
NOTE Confidence: 0.889315382857143
00:04:40.040 --> 00:04:42.260 on treatment vaccination mounted
NOTE Confidence: 0.889315382857143
00:04:42.350 --> 00:04:45.170 antibody response after two doses.
NOTE Confidence: 0.889315382857143
00:04:45.170 --> 00:04:47.906 When you look at what those therapies were,
NOTE Confidence: 0.889315382857143
00:04:47.910 --> 00:04:49.810 the vast majority of patients
NOTE Confidence: 0.889315382857143
00:04:49.810 --> 00:04:51.710 were on BTK continues BTK,
NOTE Confidence: 0.889315382857143
00:04:51.710 --> 00:04:52.842 and in those patients,
NOTE Confidence: 0.889315382857143
00:04:52.842 --> 00:04:55.130 just 22% of patients mounted antibody
NOTE Confidence: 0.889315382857143
00:04:55.130 --> 00:04:56.850 response after two vaccinations.
NOTE Confidence: 0.889315382857143
00:04:56.850 --> 00:04:58.330 If you're on Phenetics,
NOTE Confidence: 0.889315382857143
00:04:58.330 --> 00:04:59.810 monotherapy is about 50%,
NOTE Confidence: 0.889315382857143
00:04:59.810 --> 00:05:02.290 and if you run vanetta clicks along with
NOTE Confidence: 0.889315382857143

00:05:02.290 --> 00:05:04.346 either anti CD 20 or BTK inhibitor,
NOTE Confidence: 0.889315382857143

00:05:04.350 --> 00:05:07.176 there was really very minimal or
NOTE Confidence: 0.889315382857143

00:05:07.176 --> 00:05:10.253 no response in terms of human
NOTE Confidence: 0.889315382857143

00:05:10.253 --> 00:05:12.445 response to to vaccinations.
NOTE Confidence: 0.889315382857143

00:05:12.450 --> 00:05:14.358 Now you might think that we've
NOTE Confidence: 0.889315382857143

00:05:14.358 --> 00:05:15.630 moved beyond two vaccinations.
NOTE Confidence: 0.889315382857143

00:05:15.630 --> 00:05:16.317 We've done three.
NOTE Confidence: 0.889315382857143

00:05:16.317 --> 00:05:17.920 We've done 4 here in the United
NOTE Confidence: 0.889315382857143

00:05:17.970 --> 00:05:19.138 States from our patients.
NOTE Confidence: 0.889315382857143

00:05:19.140 --> 00:05:21.030 This data did look at patients that
NOTE Confidence: 0.889315382857143

00:05:21.030 --> 00:05:22.630 had no response to two vaccinations
NOTE Confidence: 0.889315382857143

00:05:22.630 --> 00:05:24.710 that then went on to get a third,
NOTE Confidence: 0.889315382857143

00:05:24.710 --> 00:05:27.139 just about 1/4 of patients will will
NOTE Confidence: 0.889315382857143

00:05:27.139 --> 00:05:29.062 respond to 1/3 dose, and again,
NOTE Confidence: 0.889315382857143

00:05:29.062 --> 00:05:30.478 most of those responses were seen
NOTE Confidence: 0.889315382857143

00:05:30.478 --> 00:05:32.134 in the treatment, naive CLL,

NOTE Confidence: 0.889315382857143
00:05:32.134 --> 00:05:34.126 or those that were off treatment.
NOTE Confidence: 0.889315382857143
00:05:34.130 --> 00:05:35.790 If you were on therapy,
NOTE Confidence: 0.889315382857143
00:05:35.790 --> 00:05:37.857 you had only about a 25% chance
NOTE Confidence: 0.889315382857143
00:05:37.857 --> 00:05:39.892 of mounting antibody response to
NOTE Confidence: 0.889315382857143
00:05:39.892 --> 00:05:41.520 three doses of vaccine.
NOTE Confidence: 0.854066936
00:05:44.050 --> 00:05:46.101 So that data really goes nicely with
NOTE Confidence: 0.854066936
00:05:46.101 --> 00:05:47.668 what's been reported at smaller
NOTE Confidence: 0.854066936
00:05:47.668 --> 00:05:49.576 institution studies here in United States
NOTE Confidence: 0.854066936
00:05:49.576 --> 00:05:51.657 have been published in the last year.
NOTE Confidence: 0.854066936
00:05:51.660 --> 00:05:53.420 What we really didn't have is a lot
NOTE Confidence: 0.854066936
00:05:53.420 --> 00:05:55.408 of data in other independent farmers,
NOTE Confidence: 0.854066936
00:05:55.410 --> 00:05:58.479 and so this was very nice data from Doctor
NOTE Confidence: 0.854066936
00:05:58.479 --> 00:06:01.134 Beaton from Australia that presented data
NOTE Confidence: 0.854066936
00:06:01.134 --> 00:06:03.758 looking at waldenstrom's patients as well
NOTE Confidence: 0.854066936
00:06:03.758 --> 00:06:06.350 as Flickr lymphoma patients in Australia.
NOTE Confidence: 0.854066936

00:06:06.350 --> 00:06:09.605 So smaller study only about 34 patients
NOTE Confidence: 0.854066936

00:06:09.605 --> 00:06:12.432 with follicular 37 with waldenstrom's about
NOTE Confidence: 0.854066936

00:06:12.432 --> 00:06:16.009 1/3 of patients had been treatment naive.
NOTE Confidence: 0.854066936

00:06:16.010 --> 00:06:18.195 Many of those in follicular
NOTE Confidence: 0.854066936

00:06:18.195 --> 00:06:19.506 had had immunotherapy,
NOTE Confidence: 0.854066936

00:06:19.510 --> 00:06:22.234 including some that had just completed
NOTE Confidence: 0.854066936

00:06:22.234 --> 00:06:24.950 treatment a few months previously.
NOTE Confidence: 0.854066936

00:06:24.950 --> 00:06:27.583 BTK was quite common in the Waldenstrom's
NOTE Confidence: 0.854066936

00:06:27.583 --> 00:06:29.475 group and fairly representative
NOTE Confidence: 0.854066936

00:06:29.475 --> 00:06:31.840 population for our patients with
NOTE Confidence: 0.854066936

00:06:31.901 --> 00:06:34.250 follicular and waldenstrom's.
NOTE Confidence: 0.854066936

00:06:34.250 --> 00:06:36.469 Not only did they have antibody titers,
NOTE Confidence: 0.854066936

00:06:36.470 --> 00:06:38.486 but they also did some neutralization assays.
NOTE Confidence: 0.854066936

00:06:38.490 --> 00:06:39.729 I'm not going to present that data,
NOTE Confidence: 0.854066936

00:06:39.730 --> 00:06:41.308 but really there was strong correlation.
NOTE Confidence: 0.854066936

00:06:41.310 --> 00:06:44.076 So for antibody titers and neutralization

NOTE Confidence: 0.854066936

00:06:44.076 --> 00:06:47.344 correlated quite well and they also had some

NOTE Confidence: 0.854066936

00:06:47.344 --> 00:06:50.198 T cell acids that I'll present at the end.

NOTE Confidence: 0.854066936

00:06:50.200 --> 00:06:53.264 This is just the antibody titers for patients

NOTE Confidence: 0.854066936

00:06:53.264 --> 00:06:56.157 that had in a chemotherapy compared to

NOTE Confidence: 0.854066936

00:06:56.160 --> 00:06:58.878 treatment naive compared to healthy controls.

NOTE Confidence: 0.854066936

00:06:58.880 --> 00:07:00.040 And really the treatment naive.

NOTE Confidence: 0.854066936

00:07:00.040 --> 00:07:01.524 Whether you had waldenstrom's

NOTE Confidence: 0.854066936

00:07:01.524 --> 00:07:02.637 or for lymphoma,

NOTE Confidence: 0.854066936

00:07:02.640 --> 00:07:04.210 their antibody titers were very

NOTE Confidence: 0.854066936

00:07:04.210 --> 00:07:05.780 similar to the healthy controls.

NOTE Confidence: 0.854066936

00:07:05.780 --> 00:07:07.345 But if you were getting

NOTE Confidence: 0.854066936

00:07:07.345 --> 00:07:08.597 immunochemotherapy within six months

NOTE Confidence: 0.854066936

00:07:08.597 --> 00:07:10.460 of completing immunochemotherapy,

NOTE Confidence: 0.854066936

00:07:10.460 --> 00:07:12.055 there was really significantly reduced

NOTE Confidence: 0.854066936

00:07:12.055 --> 00:07:14.219 antibody titers and they had very few

NOTE Confidence: 0.854066936

00:07:14.219 --> 00:07:15.755 patients getting a bit of tourism.

NOTE Confidence: 0.854066936

00:07:15.760 --> 00:07:17.776 But it did look like that response

NOTE Confidence: 0.854066936

00:07:17.776 --> 00:07:19.533 or reduction in antibody titers

NOTE Confidence: 0.854066936

00:07:19.533 --> 00:07:20.778 persisted quite far.

NOTE Confidence: 0.854066936

00:07:20.780 --> 00:07:22.600 They had one patient that was 21.

NOTE Confidence: 0.854066936

00:07:22.600 --> 00:07:24.046 Months out from finishing up in

NOTE Confidence: 0.854066936

00:07:24.046 --> 00:07:26.048 a tourism map that still did not

NOTE Confidence: 0.854066936

00:07:26.048 --> 00:07:27.035 mountain antibody response.

NOTE Confidence: 0.736526830769231

00:07:29.250 --> 00:07:31.483 This is there kind of a snapshot

NOTE Confidence: 0.736526830769231

00:07:31.483 --> 00:07:33.370 of their functional T cell assays,

NOTE Confidence: 0.736526830769231

00:07:33.370 --> 00:07:35.368 and So what they had was

NOTE Confidence: 0.736526830769231

00:07:35.370 --> 00:07:37.022 peripheral blood mononuclear cells,

NOTE Confidence: 0.736526830769231

00:07:37.022 --> 00:07:39.087 pre vaccination and then post

NOTE Confidence: 0.736526830769231

00:07:39.087 --> 00:07:40.848 vaccination and revaccination there.

NOTE Confidence: 0.736526830769231

00:07:40.850 --> 00:07:42.535 Really there was no stimulation

NOTE Confidence: 0.736526830769231

00:07:42.535 --> 00:07:45.954 of the T cells when these T cells

NOTE Confidence: 0.736526830769231
00:07:45.954 --> 00:07:48.158 were subjugated to COVID peptides.
NOTE Confidence: 0.736526830769231
00:07:48.158 --> 00:07:51.630 But in all patients which was encouraging,
NOTE Confidence: 0.736526830769231
00:07:51.630 --> 00:07:54.059 they did see signs of activation in
NOTE Confidence: 0.736526830769231
00:07:54.059 --> 00:07:56.281 the post vaccination and so this
NOTE Confidence: 0.736526830769231
00:07:56.281 --> 00:07:58.141 data suggested that these patients
NOTE Confidence: 0.736526830769231
00:07:58.141 --> 00:07:59.938 with Wellness drums and flick.
NOTE Confidence: 0.736526830769231
00:07:59.940 --> 00:08:02.467 At least have some T cell education
NOTE Confidence: 0.736526830769231
00:08:02.467 --> 00:08:03.550 with the vaccination.
NOTE Confidence: 0.939563118333333
00:08:06.210 --> 00:08:08.370 So just to kind of summarize,
NOTE Confidence: 0.939563118333333
00:08:08.370 --> 00:08:10.380 both the the ASH presentations but
NOTE Confidence: 0.939563118333333
00:08:10.380 --> 00:08:13.306 also kind of the the growing data into
NOTE Confidence: 0.939563118333333
00:08:13.306 --> 00:08:16.092 lymphomas in CLL and COVID is that
NOTE Confidence: 0.939563118333333
00:08:16.092 --> 00:08:18.370 patients with indolent lymphomas,
NOTE Confidence: 0.939563118333333
00:08:18.370 --> 00:08:19.742 particularly CLL at baseline,
NOTE Confidence: 0.939563118333333
00:08:19.742 --> 00:08:21.800 have lower human response to COVID
NOTE Confidence: 0.939563118333333

00:08:21.857 --> 00:08:24.107 vaccinations compared to healthy controls.

NOTE Confidence: 0.939563118333333

00:08:24.110 --> 00:08:25.870 Despite I think limited and

NOTE Confidence: 0.939563118333333

00:08:25.870 --> 00:08:27.630 relatively mixed T cell data,

NOTE Confidence: 0.939563118333333

00:08:27.630 --> 00:08:29.148 there really is very little downside

NOTE Confidence: 0.939563118333333

00:08:29.148 --> 00:08:30.770 of giving our patients vaccinations,

NOTE Confidence: 0.939563118333333

00:08:30.770 --> 00:08:32.258 and so all vaccine.

NOTE Confidence: 0.939563118333333

00:08:32.258 --> 00:08:34.118 All unvaccinated patients that come

NOTE Confidence: 0.939563118333333

00:08:34.118 --> 00:08:36.440 through your office with these diseases.

NOTE Confidence: 0.939563118333333

00:08:36.440 --> 00:08:38.106 Need to be cancelled every time you

NOTE Confidence: 0.939563118333333

00:08:38.106 --> 00:08:39.953 see them to really educate them to

NOTE Confidence: 0.939563118333333

00:08:39.953 --> 00:08:41.902 try to get them vaccinated and then

NOTE Confidence: 0.939563118333333

00:08:41.902 --> 00:08:43.594 even in those that are vaccinated,

NOTE Confidence: 0.939563118333333

00:08:43.600 --> 00:08:44.398 the vaccine itself,

NOTE Confidence: 0.939563118333333

00:08:44.398 --> 00:08:45.994 I mean actually not be producing

NOTE Confidence: 0.939563118333333

00:08:45.994 --> 00:08:47.600 a huge amount of protection,

NOTE Confidence: 0.939563118333333

00:08:47.600 --> 00:08:49.865 and so I'm having discussions

NOTE Confidence: 0.939563118333333
00:08:49.865 --> 00:08:51.677 about precautions and having
NOTE Confidence: 0.939563118333333
00:08:51.677 --> 00:08:53.651 discussions about use of prophylaxis,
NOTE Confidence: 0.939563118333333
00:08:53.651 --> 00:08:55.913 including heavy shelter here at Yale.
NOTE Confidence: 0.939563118333333
00:08:55.920 --> 00:08:58.056 We have this heavy shield COVID
NOTE Confidence: 0.939563118333333
00:08:58.056 --> 00:09:00.098 prophylaxis panel order set that is
NOTE Confidence: 0.939563118333333
00:09:00.098 --> 00:09:02.314 quite helpful in will kind of walk you
NOTE Confidence: 0.939563118333333
00:09:02.383 --> 00:09:05.036 through getting every shell to our patients.
NOTE Confidence: 0.939563118333333
00:09:05.040 --> 00:09:06.150 I also think it's important
NOTE Confidence: 0.939563118333333
00:09:06.150 --> 00:09:06.816 to recognize that.
NOTE Confidence: 0.939563118333333
00:09:06.820 --> 00:09:08.580 Treatments used for our diseases.
NOTE Confidence: 0.939563118333333
00:09:08.580 --> 00:09:10.336 Skeletal infamous likely have
NOTE Confidence: 0.939563118333333
00:09:10.336 --> 00:09:12.092 differential impact on human
NOTE Confidence: 0.939563118333333
00:09:12.092 --> 00:09:14.229 response to color vaccinations.
NOTE Confidence: 0.939563118333333
00:09:14.230 --> 00:09:15.004 Not surprisingly,
NOTE Confidence: 0.939563118333333
00:09:15.004 --> 00:09:18.748 anti CD 20 can really lead to low antibody
NOTE Confidence: 0.939563118333333

00:09:18.748 --> 00:09:21.305 titers after vaccination for 6:12,
NOTE Confidence: 0.939563118333333

00:09:21.305 --> 00:09:22.220 perhaps even longer.
NOTE Confidence: 0.939563118333333

00:09:22.220 --> 00:09:24.730 It is important to to kind of think
NOTE Confidence: 0.939563118333333

00:09:24.730 --> 00:09:26.590 about and then also maybe more
NOTE Confidence: 0.939563118333333

00:09:26.590 --> 00:09:28.427 surprising was the use of BTK so
NOTE Confidence: 0.939563118333333

00:09:28.427 --> 00:09:30.424 people in Bteq seem to have lower
NOTE Confidence: 0.939563118333333

00:09:30.424 --> 00:09:32.956 responsive to go vaccinations as well,
NOTE Confidence: 0.939563118333333

00:09:32.960 --> 00:09:34.824 and so because to this all of our
NOTE Confidence: 0.939563118333333

00:09:34.824 --> 00:09:36.184 patients with CLL and lymphomas
NOTE Confidence: 0.939563118333333

00:09:36.184 --> 00:09:37.870 really need to be educated about.
NOTE Confidence: 0.939563118333333

00:09:37.870 --> 00:09:39.230 Early identification of COVID
NOTE Confidence: 0.939563118333333

00:09:39.230 --> 00:09:41.270 illness as well as perhaps using
NOTE Confidence: 0.939563118333333

00:09:41.332 --> 00:09:43.090 outpatient treatment strategies.
NOTE Confidence: 0.939563118333333

00:09:43.090 --> 00:09:43.930 Monoclonal antibodies,
NOTE Confidence: 0.939563118333333

00:09:43.930 --> 00:09:45.190 antivirals, I think,
NOTE Confidence: 0.939563118333333

00:09:45.190 --> 00:09:45.573 actually,

NOTE Confidence: 0.939563118333333

00:09:45.573 --> 00:09:48.637 that is a key take away for managing

NOTE Confidence: 0.939563118333333

00:09:48.637 --> 00:09:51.455 patients with CLL and lymphomas these days.

NOTE Confidence: 0.909959435

00:09:53.500 --> 00:09:54.860 So there's going to be a couple studies.

NOTE Confidence: 0.909959435

00:09:54.860 --> 00:09:56.050 Hopefully reading out this later

NOTE Confidence: 0.909959435

00:09:56.050 --> 00:09:58.004 this year that will help give us a

NOTE Confidence: 0.909959435

00:09:58.004 --> 00:09:59.194 little more information about our

NOTE Confidence: 0.909959435

00:09:59.194 --> 00:10:00.600 patients that are immunosuppressed.

NOTE Confidence: 0.909959435

00:10:00.600 --> 00:10:02.316 The melody study is a massive

NOTE Confidence: 0.909959435

00:10:02.316 --> 00:10:03.914 valuation of lateral flow immunoassays

NOTE Confidence: 0.909959435

00:10:03.914 --> 00:10:05.909 and detecting antibodies to SARS,

NOTE Confidence: 0.909959435

00:10:05.910 --> 00:10:08.150 Co V2 and this is a large

NOTE Confidence: 0.909959435

00:10:08.150 --> 00:10:09.860 community based study in the UK.

NOTE Confidence: 0.909959435

00:10:09.860 --> 00:10:11.545 So about 35,000 patients were

NOTE Confidence: 0.909959435

00:10:11.545 --> 00:10:13.230 enrolled and they're going to

NOTE Confidence: 0.909959435

00:10:13.289 --> 00:10:14.859 be looking at antibody response

NOTE Confidence: 0.909959435

00:10:14.859 --> 00:10:17.452 to three and four doses of M RNA
NOTE Confidence: 0.909959435

00:10:17.452 --> 00:10:19.057 vaccine and then really importantly,
NOTE Confidence: 0.909959435

00:10:19.060 --> 00:10:20.915 they're going to look at whether the
NOTE Confidence: 0.909959435

00:10:20.915 --> 00:10:22.481 lack of antibody response correlate's
NOTE Confidence: 0.909959435

00:10:22.481 --> 00:10:24.407 with the risk of COVID-19 infection.
NOTE Confidence: 0.909959435

00:10:24.410 --> 00:10:26.390 As well, severity of disease.
NOTE Confidence: 0.909959435

00:10:26.390 --> 00:10:27.910 There's also an important study
NOTE Confidence: 0.909959435

00:10:27.910 --> 00:10:29.882 for our patients with CLL BTK'S,
NOTE Confidence: 0.909959435

00:10:29.882 --> 00:10:31.386 which public Tribeca study.
NOTE Confidence: 0.909959435

00:10:31.390 --> 00:10:32.470 This is out of Australia,
NOTE Confidence: 0.909959435

00:10:32.470 --> 00:10:34.678 where they're basically going to stop
NOTE Confidence: 0.909959435

00:10:34.678 --> 00:10:36.668 patients on their BTK temporarily
NOTE Confidence: 0.909959435

00:10:36.668 --> 00:10:38.464 vaccinate them with different
NOTE Confidence: 0.909959435

00:10:38.464 --> 00:10:41.280 strategies in terms of holding the BTK,
NOTE Confidence: 0.909959435

00:10:41.280 --> 00:10:44.024 ideally to identify ways of allowing our
NOTE Confidence: 0.909959435

00:10:44.024 --> 00:10:47.327 BTK patients to Mona a nice antibody

NOTE Confidence: 0.909959435

00:10:47.327 --> 00:10:49.892 response following vaccination against Kovan.

NOTE Confidence: 0.909959435

00:10:49.900 --> 00:10:51.164 So, given this uncertainty,

NOTE Confidence: 0.909959435

00:10:51.164 --> 00:10:53.060 given the fact that our patients

NOTE Confidence: 0.909959435

00:10:53.119 --> 00:10:55.368 typically do very well with a

NOTE Confidence: 0.909959435

00:10:55.368 --> 00:10:57.000 current modern therapeutics,

NOTE Confidence: 0.909959435

00:10:57.000 --> 00:10:58.600 I've generally recommended fixed duration

NOTE Confidence: 0.909959435

00:10:58.600 --> 00:11:00.779 without maintenance for most of my patients,

NOTE Confidence: 0.909959435

00:11:00.780 --> 00:11:02.700 and so when we think about fixed duration,

NOTE Confidence: 0.909959435

00:11:02.700 --> 00:11:03.684 lack of maintenance,

NOTE Confidence: 0.909959435

00:11:03.684 --> 00:11:05.980 was there any studies that ash that

NOTE Confidence: 0.909959435

00:11:06.046 --> 00:11:07.760 might influence our therapies going

NOTE Confidence: 0.909959435

00:11:07.760 --> 00:11:09.535 forward and there certainly were,

NOTE Confidence: 0.909959435

00:11:09.540 --> 00:11:12.235 and I'll focus on those in the

NOTE Confidence: 0.909959435

00:11:12.235 --> 00:11:13.390 next few slides.

NOTE Confidence: 0.909959435

00:11:13.390 --> 00:11:15.244 So this was an important study

NOTE Confidence: 0.909959435

00:11:15.244 --> 00:11:16.480 presented by Doctor Eickhorst,
NOTE Confidence: 0.909959435

00:11:16.480 --> 00:11:18.880 which was a CLL 13 study.
NOTE Confidence: 0.909959435

00:11:18.880 --> 00:11:21.178 This was a large randomized European
NOTE Confidence: 0.909959435

00:11:21.178 --> 00:11:23.310 study where patients without deletion,
NOTE Confidence: 0.909959435

00:11:23.310 --> 00:11:27.564 segmenting P without TP 53
NOTE Confidence: 0.909959435

00:11:27.564 --> 00:11:29.872 mutations were randomized either
NOTE Confidence: 0.909959435

00:11:29.872 --> 00:11:32.180 to standard IMMUNOCHEMOTHERAPY FC
NOTE Confidence: 0.909959435

00:11:32.264 --> 00:11:34.589 RVR or Vertex magnetic locks.
NOTE Confidence: 0.909959435

00:11:34.590 --> 00:11:35.738 Or the triplet venetoclax
NOTE Confidence: 0.909959435

00:11:35.738 --> 00:11:36.886 of Britain have been,
NOTE Confidence: 0.909959435

00:11:36.890 --> 00:11:39.144 and I've been a choose him out.
NOTE Confidence: 0.909959435

00:11:39.150 --> 00:11:40.470 Standard dosing so patients
NOTE Confidence: 0.909959435

00:11:40.470 --> 00:11:42.770 got six months of anti CD 20s.
NOTE Confidence: 0.909959435

00:11:42.770 --> 00:11:44.396 They got 12 cycles of venetoclax
NOTE Confidence: 0.909959435

00:11:44.396 --> 00:11:46.374 and then for Brewton if if people
NOTE Confidence: 0.909959435

00:11:46.374 --> 00:11:47.486 were still under deposit.

NOTE Confidence: 0.909959435

00:11:47.490 --> 00:11:49.434 If people could get up to 36 cycles.

NOTE Confidence: 0.831199428333333

00:11:52.050 --> 00:11:53.610 So the primary outcome was a.

NOTE Confidence: 0.831199428333333

00:11:53.610 --> 00:11:56.788 It was a 2 coprimary outcomes MRD,

NOTE Confidence: 0.831199428333333

00:11:56.790 --> 00:11:58.260 undetectable rate of 15 months,

NOTE Confidence: 0.831199428333333

00:11:58.260 --> 00:12:00.768 as well as PFS. Not surprisingly,

NOTE Confidence: 0.831199428333333

00:12:00.770 --> 00:12:02.639 with this kind of early follow-up that

NOTE Confidence: 0.831199428333333

00:12:02.639 --> 00:12:04.388 PFS has interim that's assessment hasn't

NOTE Confidence: 0.831199428333333

00:12:04.388 --> 00:12:06.770 been reached and so that's still to come,

NOTE Confidence: 0.831199428333333

00:12:06.770 --> 00:12:09.266 but they didn't have the 15 month MRD

NOTE Confidence: 0.831199428333333

00:12:09.266 --> 00:12:11.758 data that they presented at Ash and what

NOTE Confidence: 0.831199428333333

00:12:11.758 --> 00:12:14.945 we see here is that the peripheral blood

NOTE Confidence: 0.831199428333333

00:12:14.945 --> 00:12:17.345 flow cytometry based undetectable Mardi

NOTE Confidence: 0.831199428333333

00:12:17.350 --> 00:12:21.868 was 86% in the jivan arm and 92.2%.

NOTE Confidence: 0.831199428333333

00:12:21.868 --> 00:12:24.004 Can be tripled arm both the

NOTE Confidence: 0.831199428333333

00:12:24.004 --> 00:12:25.756 community therapy as well as RTX.

NOTE Confidence: 0.831199428333333

00:12:25.760 --> 00:12:28.616 Magnetic locks had lower around 50%
NOTE Confidence: 0.8311994283333333

00:12:28.620 --> 00:12:31.112 and overall this there was two positive
NOTE Confidence: 0.8311994283333333

00:12:31.112 --> 00:12:33.660 alarms compared to the immunochemotherapy.
NOTE Confidence: 0.8311994283333333

00:12:33.660 --> 00:12:37.788 Both the G Ven and Gebruik infinite clocks.
NOTE Confidence: 0.8311994283333333

00:12:37.790 --> 00:12:40.961 There was a kind of companion MRD
NOTE Confidence: 0.8311994283333333

00:12:40.961 --> 00:12:43.046 assessment presentation which I think
NOTE Confidence: 0.8311994283333333

00:12:43.046 --> 00:12:45.398 was was was quite interesting where
NOTE Confidence: 0.8311994283333333

00:12:45.398 --> 00:12:48.657 they looked at MRD by the CLL molecular
NOTE Confidence: 0.8311994283333333

00:12:48.657 --> 00:12:51.811 phenotype and what we can see here is
NOTE Confidence: 0.8311994283333333

00:12:51.811 --> 00:12:53.976 that the molecular subtypes of seal
NOTE Confidence: 0.8311994283333333

00:12:53.976 --> 00:12:56.482 that typically do much better with a
NOTE Confidence: 0.8311994283333333

00:12:56.482 --> 00:12:58.022 brute compared to immunochemotherapy
NOTE Confidence: 0.8311994283333333

00:12:58.022 --> 00:12:59.684 do better on the trip with the arm.
NOTE Confidence: 0.8311994283333333

00:12:59.690 --> 00:13:02.248 So patients that are 11 Q patients
NOTE Confidence: 0.8311994283333333

00:13:02.248 --> 00:13:04.334 that are unmutated have at least kind
NOTE Confidence: 0.8311994283333333

00:13:04.334 --> 00:13:06.576 of a 1010 absolute percent increase

NOTE Confidence: 0.831199428333333
00:13:06.576 --> 00:13:08.556 of them are deemed detectable.
NOTE Confidence: 0.831199428333333
00:13:08.560 --> 00:13:11.178 With the triplet compared to the double
NOTE Confidence: 0.831199428333333
00:13:11.178 --> 00:13:13.632 ARM patients that have the lower risk
NOTE Confidence: 0.831199428333333
00:13:13.632 --> 00:13:16.249 disease in terms of being IG HV mutated
NOTE Confidence: 0.831199428333333
00:13:16.250 --> 00:13:18.889 seem to have relatively similar energy rates.
NOTE Confidence: 0.831199428333333
00:13:18.890 --> 00:13:20.730 Whether you get the doublet or the triplet.
NOTE Confidence: 0.772712632222222
00:13:23.240 --> 00:13:24.554 This energy does come at some
NOTE Confidence: 0.772712632222222
00:13:24.554 --> 00:13:25.930 toxicity in terms of the triple
NOTE Confidence: 0.772712632222222
00:13:25.930 --> 00:13:27.280 arm compared to the double it,
NOTE Confidence: 0.772712632222222
00:13:27.280 --> 00:13:29.152 and so things like febrile neutropenic
NOTE Confidence: 0.772712632222222
00:13:29.152 --> 00:13:30.755 infections were higher in the
NOTE Confidence: 0.772712632222222
00:13:30.755 --> 00:13:32.260 triplet compared to the doublets.
NOTE Confidence: 0.772712632222222
00:13:32.260 --> 00:13:33.835 And then when you add a brute
NOTE Confidence: 0.772712632222222
00:13:33.835 --> 00:13:35.377 nib you also saw a low rate,
NOTE Confidence: 0.772712632222222
00:13:35.380 --> 00:13:36.585 although it was there at
NOTE Confidence: 0.772712632222222

00:13:36.585 --> 00:13:37.730 2% in terms of eight Feb.
NOTE Confidence: 0.924631176666667

00:13:40.330 --> 00:13:42.176 So in terms of the summary, and take
NOTE Confidence: 0.924631176666667

00:13:42.176 --> 00:13:44.960 away was that in terms of MRD status,
NOTE Confidence: 0.924631176666667

00:13:44.960 --> 00:13:47.720 the advantage choosing venetoclax
NOTE Confidence: 0.924631176666667

00:13:47.720 --> 00:13:50.780 were superior to chemotherapy and
NOTE Confidence: 0.924631176666667

00:13:50.780 --> 00:13:52.880 there was two arms that met their
NOTE Confidence: 0.924631176666667

00:13:52.880 --> 00:13:54.621 Co primary endpoint Rituxan Venetic
NOTE Confidence: 0.924631176666667

00:13:54.621 --> 00:13:57.120 LEX was not superior in terms of
NOTE Confidence: 0.924631176666667

00:13:57.183 --> 00:13:59.547 MRD of detectable rate compared to
NOTE Confidence: 0.924631176666667

00:13:59.547 --> 00:14:01.389 the primary FCR chemotherapy arm.
NOTE Confidence: 0.924631176666667

00:14:01.389 --> 00:14:03.461 They were very happy to see that most
NOTE Confidence: 0.924631176666667

00:14:03.461 --> 00:14:05.040 patients tolerated treatment well.
NOTE Confidence: 0.924631176666667

00:14:05.040 --> 00:14:07.698 There was very low rates of
NOTE Confidence: 0.924631176666667

00:14:07.698 --> 00:14:09.830 discontinuation and although there was.
NOTE Confidence: 0.924631176666667

00:14:09.830 --> 00:14:10.442 Some increased,
NOTE Confidence: 0.924631176666667

00:14:10.442 --> 00:14:12.584 perhaps toxicity for the triplet in terms

NOTE Confidence: 0.924631176666667
00:14:12.584 --> 00:14:14.740 of infection in terms of pepperoncini,
NOTE Confidence: 0.924631176666667
00:14:14.740 --> 00:14:15.780 and generally people tolerate
NOTE Confidence: 0.924631176666667
00:14:15.780 --> 00:14:17.080 this this regimen as well.
NOTE Confidence: 0.90232694
00:14:19.580 --> 00:14:21.692 So if we think about kind of the
NOTE Confidence: 0.90232694
00:14:21.692 --> 00:14:23.420 majority of patients are older,
NOTE Confidence: 0.90232694
00:14:23.420 --> 00:14:25.055 perhaps have comedies,
NOTE Confidence: 0.90232694
00:14:25.055 --> 00:14:28.454 maybe the triplet is is is not
NOTE Confidence: 0.90232694
00:14:28.454 --> 00:14:30.659 appropriate for that patient population.
NOTE Confidence: 0.90232694
00:14:30.660 --> 00:14:31.710 Is there another fixed duration
NOTE Confidence: 0.90232694
00:14:31.710 --> 00:14:32.964 regimen that we might be able
NOTE Confidence: 0.90232694
00:14:32.964 --> 00:14:33.960 to use in the near future?
NOTE Confidence: 0.90232694
00:14:33.960 --> 00:14:34.866 And there is?
NOTE Confidence: 0.90232694
00:14:34.866 --> 00:14:37.202 This is the GLOBE study and this
NOTE Confidence: 0.90232694
00:14:37.202 --> 00:14:39.659 was a randomized trial of patients
NOTE Confidence: 0.90232694
00:14:39.659 --> 00:14:42.053 that were older or those that
NOTE Confidence: 0.90232694

00:14:42.053 --> 00:14:44.110 were younger with committees,
NOTE Confidence: 0.90232694

00:14:44.110 --> 00:14:46.648 about 210 patients or so were
NOTE Confidence: 0.90232694

00:14:46.648 --> 00:14:49.108 randomized to either have been a 2.
NOTE Confidence: 0.90232694

00:14:49.110 --> 00:14:50.138 I take that back.
NOTE Confidence: 0.90232694

00:14:50.138 --> 00:14:51.166 They are brute NIM,
NOTE Confidence: 0.90232694

00:14:51.170 --> 00:14:52.580 so a brute in bleeding for
NOTE Confidence: 0.90232694

00:14:52.580 --> 00:14:54.039 three months and then a brute
NOTE Confidence: 0.90232694

00:14:54.039 --> 00:14:55.449 in Veneta clicks for toy cycles
NOTE Confidence: 0.90232694

00:14:55.449 --> 00:14:56.800 and then everyone stopped.
NOTE Confidence: 0.90232694

00:14:56.800 --> 00:14:59.596 It was not MRD directed therapy
NOTE Confidence: 0.90232694

00:14:59.600 --> 00:15:01.148 and then the old control arm.
NOTE Confidence: 0.90232694

00:15:01.150 --> 00:15:02.760 Here is a bit mad with crab.
NOTE Confidence: 0.774811938

00:15:05.460 --> 00:15:06.730 This is the PFS data.
NOTE Confidence: 0.774811938

00:15:06.730 --> 00:15:08.626 This data has been presented earlier
NOTE Confidence: 0.774811938

00:15:08.626 --> 00:15:10.808 EHA and what the focus of this
NOTE Confidence: 0.774811938

00:15:10.808 --> 00:15:12.524 abstract was was really on them

NOTE Confidence: 0.774811938

00:15:12.524 --> 00:15:14.600 or D rates in this in this arms,

NOTE Confidence: 0.774811938

00:15:14.600 --> 00:15:16.470 so we can see sphere.

NOTE Confidence: 0.774811938

00:15:16.470 --> 00:15:19.260 Certainly clear superiority in that PFS

NOTE Confidence: 0.774811938

00:15:19.260 --> 00:15:21.620 benefit of the improvement phenetics

NOTE Confidence: 0.774811938

00:15:21.620 --> 00:15:24.158 arm compared to Carnival in two,

NOTE Confidence: 0.774811938

00:15:24.160 --> 00:15:26.096 with a median follow-up of of 34 months,

NOTE Confidence: 0.774811938

00:15:26.100 --> 00:15:27.375 although overall survival

NOTE Confidence: 0.774811938

00:15:27.375 --> 00:15:29.075 was actually down tickle,

NOTE Confidence: 0.774811938

00:15:29.080 --> 00:15:30.662 and it'll be important to see the

NOTE Confidence: 0.774811938

00:15:30.662 --> 00:15:31.979 long term follow up from this.

NOTE Confidence: 0.774811938

00:15:31.980 --> 00:15:32.848 This study as well.

NOTE Confidence: 0.765406958

00:15:34.870 --> 00:15:36.440 That instead of being flow,

NOTE Confidence: 0.765406958

00:15:36.440 --> 00:15:38.600 they used NGS a little bit more sensitive

NOTE Confidence: 0.765406958

00:15:38.600 --> 00:15:40.870 and a little bit more reproducible.

NOTE Confidence: 0.765406958

00:15:40.870 --> 00:15:42.571 And what we see here is that

NOTE Confidence: 0.765406958

00:15:42.571 --> 00:15:44.480 the rates of them are detectable
NOTE Confidence: 0.765406958

00:15:44.480 --> 00:15:46.335 with this doublet oral double.
NOTE Confidence: 0.765406958

00:15:46.340 --> 00:15:48.629 It was about 50% in the peripheral
NOTE Confidence: 0.765406958

00:15:48.629 --> 00:15:50.779 blood as well as develop Mira,
NOTE Confidence: 0.765406958

00:15:50.780 --> 00:15:53.110 and that was statistically significantly
NOTE Confidence: 0.765406958

00:15:53.110 --> 00:15:54.974 improved over claim Bissell.
NOTE Confidence: 0.765406958

00:15:54.980 --> 00:15:58.220 And it's also notable that the
NOTE Confidence: 0.765406958

00:15:58.220 --> 00:15:59.960 concordance of bone marrow to
NOTE Confidence: 0.765406958

00:16:00.028 --> 00:16:01.708 preferred blood MRD was much
NOTE Confidence: 0.765406958

00:16:01.708 --> 00:16:03.995 higher in the doublet arm compared
NOTE Confidence: 0.765406958

00:16:03.995 --> 00:16:05.627 to the immunochemotherapy.
NOTE Confidence: 0.765406958

00:16:05.630 --> 00:16:06.210 A pharmacy.
NOTE Confidence: 0.864281604285714

00:16:09.330 --> 00:16:11.017 For patients that I think are thinking
NOTE Confidence: 0.864281604285714

00:16:11.017 --> 00:16:13.085 about PFS and how long they're going to
NOTE Confidence: 0.864281604285714

00:16:13.085 --> 00:16:14.900 be in remission after stopping treatment,
NOTE Confidence: 0.864281604285714

00:16:14.900 --> 00:16:16.937 I think this was a really important

NOTE Confidence: 0.864281604285714
00:16:16.937 --> 00:16:18.439 key addition of the study,
NOTE Confidence: 0.864281604285714
00:16:18.440 --> 00:16:22.168 which was everyone stopped a therapy in at
NOTE Confidence: 0.864281604285714
00:16:22.168 --> 00:16:25.278 certainly about 30-30 months of follow up.
NOTE Confidence: 0.864281604285714
00:16:25.280 --> 00:16:27.114 Here you can see that patients that
NOTE Confidence: 0.864281604285714
00:16:27.114 --> 00:16:29.243 were still in more detectable at the
NOTE Confidence: 0.864281604285714
00:16:29.243 --> 00:16:30.848 time of stopping therapy maintained
NOTE Confidence: 0.864281604285714
00:16:30.848 --> 00:16:32.780 a response without progression,
NOTE Confidence: 0.864281604285714
00:16:32.780 --> 00:16:33.776 and so this was, I think,
NOTE Confidence: 0.864281604285714
00:16:33.780 --> 00:16:35.660 important finding moving forward.
NOTE Confidence: 0.902005453846154
00:16:37.950 --> 00:16:40.148 And together with GLOW study as well
NOTE Confidence: 0.902005453846154
00:16:40.148 --> 00:16:42.510 as other phase two studies captivate.
NOTE Confidence: 0.902005453846154
00:16:42.510 --> 00:16:44.600 For instance, it's possible that
NOTE Confidence: 0.902005453846154
00:16:44.600 --> 00:16:47.124 we'll see additional labels of doublet
NOTE Confidence: 0.902005453846154
00:16:47.124 --> 00:16:49.284 or or doublet later this year,
NOTE Confidence: 0.902005453846154
00:16:49.290 --> 00:16:50.704 and I would stay tuned to see
NOTE Confidence: 0.902005453846154

00:16:50.704 --> 00:16:52.012 whether that could be incorporated
NOTE Confidence: 0.902005453846154

00:16:52.012 --> 00:16:52.996 into standard practice.
NOTE Confidence: 0.649605598181818

00:16:55.300 --> 00:16:56.452 So when we think about flicking
NOTE Confidence: 0.649605598181818

00:16:56.452 --> 00:16:57.600 them from and fixed duration,
NOTE Confidence: 0.649605598181818

00:16:57.600 --> 00:16:59.700 we're really more thinking about the
NOTE Confidence: 0.649605598181818

00:16:59.700 --> 00:17:02.604 anti CD 20 in terms of maintenance
NOTE Confidence: 0.649605598181818

00:17:02.604 --> 00:17:05.070 Rituxan mount and this was an important
NOTE Confidence: 0.649605598181818

00:17:05.070 --> 00:17:06.960 update from Doctor Call from Washington
NOTE Confidence: 0.649605598181818

00:17:06.960 --> 00:17:08.880 St Louis of the Resort study.
NOTE Confidence: 0.649605598181818

00:17:08.880 --> 00:17:10.338 So this was a randomized study
NOTE Confidence: 0.649605598181818

00:17:10.338 --> 00:17:12.089 done here in the United States.
NOTE Confidence: 0.649605598181818

00:17:12.090 --> 00:17:13.890 Patients had low burden of silicone
NOTE Confidence: 0.649605598181818

00:17:13.890 --> 00:17:15.400 phomma they all received four
NOTE Confidence: 0.649605598181818

00:17:15.400 --> 00:17:16.700 weekly doses and Rituxan mab
NOTE Confidence: 0.649605598181818

00:17:16.700 --> 00:17:18.340 and then they were randomized.
NOTE Confidence: 0.649605598181818

00:17:18.340 --> 00:17:22.407 If patients had a stable disease or

NOTE Confidence: 0.649605598181818
00:17:22.407 --> 00:17:24.690 better in patients either got rituximab.
NOTE Confidence: 0.649605598181818
00:17:24.690 --> 00:17:26.478 Monotherapy every three months,
NOTE Confidence: 0.649605598181818
00:17:26.478 --> 00:17:28.266 indefinitely until progression or
NOTE Confidence: 0.649605598181818
00:17:28.266 --> 00:17:30.457 they were on active surveillance
NOTE Confidence: 0.649605598181818
00:17:30.457 --> 00:17:32.726 with re treatment with rituximab and
NOTE Confidence: 0.649605598181818
00:17:32.726 --> 00:17:34.238 this was a one to one randomization.
NOTE Confidence: 0.915858376666667
00:17:36.890 --> 00:17:39.266 This data was originally published in
NOTE Confidence: 0.915858376666667
00:17:39.270 --> 00:17:41.552 JCM 2014 and the conclusions are here
NOTE Confidence: 0.915858376666667
00:17:41.552 --> 00:17:43.316 where basically Rituxan every treatment
NOTE Confidence: 0.915858376666667
00:17:43.316 --> 00:17:45.146 was as effective as maintenance.
NOTE Confidence: 0.915858376666667
00:17:45.150 --> 00:17:47.246 Rituximab for treatment failure.
NOTE Confidence: 0.915858376666667
00:17:47.246 --> 00:17:48.886 However, the main instruction
NOTE Confidence: 0.915858376666667
00:17:48.886 --> 00:17:51.118 map did delay time to needing
NOTE Confidence: 0.915858376666667
00:17:51.118 --> 00:17:52.556 cytotoxic chemo and ultimately,
NOTE Confidence: 0.915858376666667
00:17:52.556 --> 00:17:53.928 as you might expect,
NOTE Confidence: 0.915858376666667

00:17:53.930 --> 00:17:55.784 there was more rituximab used in
NOTE Confidence: 0.915858376666667

00:17:55.784 --> 00:17:57.406 the maintenance compared to the
NOTE Confidence: 0.915858376666667

00:17:57.406 --> 00:17:58.639 retreatment arm a year later.
NOTE Confidence: 0.915858376666667

00:17:58.639 --> 00:17:59.797 They followed up on quality of
NOTE Confidence: 0.915858376666667

00:17:59.797 --> 00:18:01.332 life and there was really no
NOTE Confidence: 0.915858376666667

00:18:01.332 --> 00:18:02.368 difference between the maintenance,
NOTE Confidence: 0.915858376666667

00:18:02.370 --> 00:18:04.090 rituximab norm compared to the
NOTE Confidence: 0.915858376666667

00:18:04.090 --> 00:18:05.810 retreatment and based off of
NOTE Confidence: 0.915858376666667

00:18:05.878 --> 00:18:07.690 this kind of earlier follow up.
NOTE Confidence: 0.915858376666667

00:18:07.690 --> 00:18:08.324 Doctor Colin,
NOTE Confidence: 0.915858376666667

00:18:08.324 --> 00:18:09.909 his colleagues recommended that re
NOTE Confidence: 0.915858376666667

00:18:09.909 --> 00:18:11.818 treatment rather than maintenance or tuck.
NOTE Confidence: 0.915858376666667

00:18:11.820 --> 00:18:14.990 Seemab was the preferred strategy.
NOTE Confidence: 0.915858376666667

00:18:14.990 --> 00:18:16.826 So now at around 10 years of follow up,
NOTE Confidence: 0.915858376666667

00:18:16.830 --> 00:18:18.456 do we have any different signals
NOTE Confidence: 0.915858376666667

00:18:18.456 --> 00:18:20.433 here and so this was freedom from

NOTE Confidence: 0.915858376666667
00:18:20.433 --> 00:18:22.372 first sent a toxic chemo and with
NOTE Confidence: 0.915858376666667
00:18:22.429 --> 00:18:24.557 long term follow up we still see a
NOTE Confidence: 0.915858376666667
00:18:24.557 --> 00:18:26.320 separation of the curves between
NOTE Confidence: 0.915858376666667
00:18:26.320 --> 00:18:27.960 Rituxan and maintenance continuously
NOTE Confidence: 0.915858376666667
00:18:27.960 --> 00:18:30.518 compared to the RE treatment strategy.
NOTE Confidence: 0.915858376666667
00:18:30.520 --> 00:18:32.596 You also see improved duration of
NOTE Confidence: 0.915858376666667
00:18:32.596 --> 00:18:34.711 response and so 66% of patients
NOTE Confidence: 0.915858376666667
00:18:34.711 --> 00:18:36.853 treated the maintenance or tux mab
NOTE Confidence: 0.915858376666667
00:18:36.860 --> 00:18:39.500 do not have progression compared to
NOTE Confidence: 0.915858376666667
00:18:39.500 --> 00:18:42.305 just 30% of patients treated with four
NOTE Confidence: 0.915858376666667
00:18:42.305 --> 00:18:45.200 doses of Rituxan have actually so much lower.
NOTE Confidence: 0.915858376666667
00:18:45.200 --> 00:18:47.426 Obviously need of Rituxan effort in
NOTE Confidence: 0.915858376666667
00:18:47.426 --> 00:18:49.380 in in administration Rituxan effort,
NOTE Confidence: 0.915858376666667
00:18:49.380 --> 00:18:51.669 the retreatment arm.
NOTE Confidence: 0.915858376666667
00:18:51.670 --> 00:18:52.552 And then,
NOTE Confidence: 0.915858376666667

00:18:52.552 --> 00:18:52.993 importantly,
NOTE Confidence: 0.915858376666667

00:18:52.993 --> 00:18:54.757 despite improvements in and
NOTE Confidence: 0.915858376666667

00:18:54.757 --> 00:18:56.540 time to cytotoxic chemo,
NOTE Confidence: 0.915858376666667

00:18:56.540 --> 00:18:58.112 the the main kind of take
NOTE Confidence: 0.915858376666667

00:18:58.112 --> 00:18:59.760 away was that oral survival,
NOTE Confidence: 0.915858376666667

00:18:59.760 --> 00:19:01.656 transformation risk secondary malignancy
NOTE Confidence: 0.915858376666667

00:19:01.656 --> 00:19:04.500 seemed very similar between the arms.
NOTE Confidence: 0.915858376666667

00:19:04.500 --> 00:19:06.551 And so the long term follow-up conclusions
NOTE Confidence: 0.915858376666667

00:19:06.551 --> 00:19:08.318 really didn't change from doctor calls.
NOTE Confidence: 0.915858376666667

00:19:08.320 --> 00:19:10.427 Mind you know it is true that
NOTE Confidence: 0.915858376666667

00:19:10.427 --> 00:19:13.157 time to send a toxic therapy was
NOTE Confidence: 0.915858376666667

00:19:13.157 --> 00:19:15.347 improved with maintenance or toxic,
NOTE Confidence: 0.915858376666667

00:19:15.350 --> 00:19:17.065 but the glass was kind of half
NOTE Confidence: 0.915858376666667

00:19:17.065 --> 00:19:19.450 half full in the sense that 63% of
NOTE Confidence: 0.915858376666667

00:19:19.450 --> 00:19:21.030 patients treated with retreatment
NOTE Confidence: 0.915858376666667

00:19:21.030 --> 00:19:23.460 remain chemo free at seven years.

NOTE Confidence: 0.915858376666667
00:19:23.460 --> 00:19:24.870 The duration response was certainly
NOTE Confidence: 0.915858376666667
00:19:24.870 --> 00:19:26.500 better with maintenance or Tux Mab,
NOTE Confidence: 0.915858376666667
00:19:26.500 --> 00:19:28.418 but he'd argued that 30% of
NOTE Confidence: 0.915858376666667
00:19:28.418 --> 00:19:29.846 patients received just 4 doses of
NOTE Confidence: 0.915858376666667
00:19:29.846 --> 00:19:31.340 rituximab in never needed treatment.
NOTE Confidence: 0.915858376666667
00:19:31.340 --> 00:19:33.200 Again for 10 plus years.
NOTE Confidence: 0.915858376666667
00:19:33.200 --> 00:19:34.960 And because overall survival
NOTE Confidence: 0.915858376666667
00:19:34.960 --> 00:19:36.280 benefit was identical.
NOTE Confidence: 0.915858376666667
00:19:36.280 --> 00:19:38.300 The treatment the Rituxan every
NOTE Confidence: 0.915858376666667
00:19:38.300 --> 00:19:39.512 treatment strategy rather
NOTE Confidence: 0.915858376666667
00:19:39.512 --> 00:19:41.309 than maintenance remained the
NOTE Confidence: 0.915858376666667
00:19:41.309 --> 00:19:43.165 recommendation of these investigators.
NOTE Confidence: 0.900593457777778
00:19:45.370 --> 00:19:48.135 So where do we stand in the spring of 2022?
NOTE Confidence: 0.900593457777778
00:19:48.135 --> 00:19:50.310 We have wonderful therapies for
NOTE Confidence: 0.900593457777778
00:19:50.310 --> 00:19:52.790 for patients with CLL and Lynn.
NOTE Confidence: 0.900593457777778

00:19:52.790 --> 00:19:54.962 On Hodgman, Thelma and we have
NOTE Confidence: 0.900593457777778

00:19:54.962 --> 00:19:57.249 to recognize that our therapy is,
NOTE Confidence: 0.900593457777778

00:19:57.250 --> 00:19:58.345 although they're wonderful,
NOTE Confidence: 0.900593457777778

00:19:58.345 --> 00:19:59.440 are not curative.
NOTE Confidence: 0.900593457777778

00:19:59.440 --> 00:20:01.690 Patients typically derive, you know,
NOTE Confidence: 0.900593457777778

00:20:01.690 --> 00:20:03.370 decade plus long benefits.
NOTE Confidence: 0.900593457777778

00:20:03.370 --> 00:20:05.470 And historically they've been poor.
NOTE Confidence: 0.900593457777778

00:20:05.470 --> 00:20:06.698 Correlation of first on
NOTE Confidence: 0.900593457777778

00:20:06.698 --> 00:20:07.926 PFS with overall survival,
NOTE Confidence: 0.900593457777778

00:20:07.930 --> 00:20:10.082 meaning that we can we can salvage our
NOTE Confidence: 0.900593457777778

00:20:10.082 --> 00:20:12.354 patients if they relapse and because of that,
NOTE Confidence: 0.900593457777778

00:20:12.354 --> 00:20:14.619 must much of my focus has been mainly.
NOTE Confidence: 0.900593457777778

00:20:14.620 --> 00:20:16.240 Maintaining good quality of life
NOTE Confidence: 0.900593457777778

00:20:16.240 --> 00:20:18.508 and and safety in there of COVID
NOTE Confidence: 0.900593457777778

00:20:18.508 --> 00:20:20.573 and what that really means is that
NOTE Confidence: 0.900593457777778

00:20:20.573 --> 00:20:22.140 actress surveillance and remains

NOTE Confidence: 0.900593457777778
00:20:22.140 --> 00:20:23.700 the standard of care for those
NOTE Confidence: 0.900593457777778
00:20:23.700 --> 00:20:25.433 that don't have clear indications
NOTE Confidence: 0.900593457777778
00:20:25.433 --> 00:20:26.977 for lymphoma directed treatment.
NOTE Confidence: 0.900593457777778
00:20:26.980 --> 00:20:29.434 It means educating patients really ad
NOTE Confidence: 0.900593457777778
00:20:29.434 --> 00:20:31.510 nausea about vaccinations and early
NOTE Confidence: 0.900593457777778
00:20:31.510 --> 00:20:33.778 COVID testing as well as therapeutics.
NOTE Confidence: 0.900593457777778
00:20:33.780 --> 00:20:35.740 And then it means if if we do need treatment,
NOTE Confidence: 0.900593457777778
00:20:35.740 --> 00:20:38.080 which certainly some do shifting more
NOTE Confidence: 0.900593457777778
00:20:38.080 --> 00:20:40.320 towards the fixed duration therapies.
NOTE Confidence: 0.900593457777778
00:20:40.320 --> 00:20:42.420 Ultimately, as we move forward,
NOTE Confidence: 0.900593457777778
00:20:42.420 --> 00:20:45.017 I think MRD is an important outcome.
NOTE Confidence: 0.900593457777778
00:20:45.020 --> 00:20:46.604 But I also think that things
NOTE Confidence: 0.900593457777778
00:20:46.604 --> 00:20:47.660 like I mean reconstitution,
NOTE Confidence: 0.900593457777778
00:20:47.660 --> 00:20:50.117 quality of life and non formal related
NOTE Confidence: 0.900593457777778
00:20:50.117 --> 00:20:51.887 mortality but really important key
NOTE Confidence: 0.900593457777778

00:20:51.887 --> 00:20:54.176 metrics as we look at the future
NOTE Confidence: 0.900593457777778

00:20:54.176 --> 00:20:55.974 readouts of clinical trials and
NOTE Confidence: 0.900593457777778

00:20:55.974 --> 00:20:58.490 so with that I will move over to
NOTE Confidence: 0.900593457777778

00:20:58.490 --> 00:21:00.275 Doctor Kothari who will lead us in
NOTE Confidence: 0.900593457777778

00:21:00.275 --> 00:21:01.926 our presentation of diffuse large
NOTE Confidence: 0.900593457777778

00:21:01.926 --> 00:21:03.924 B cell phone mantels on phone.
NOTE Confidence: 0.888663788888889

00:21:16.020 --> 00:21:17.790 Thank you Scott.
NOTE Confidence: 0.888663788888889

00:21:17.790 --> 00:21:21.330 So I'm going to present on.
NOTE Confidence: 0.888663788888889

00:21:21.330 --> 00:21:23.270 DLBCL and Mantle cell lymphoma.
NOTE Confidence: 0.888663788888889

00:21:23.270 --> 00:21:26.426 Ash 2021. Highlights and for DLBCL.
NOTE Confidence: 0.888663788888889

00:21:26.430 --> 00:21:28.548 I would like to focus on
NOTE Confidence: 0.888663788888889

00:21:28.548 --> 00:21:29.656 two frontline studies,
NOTE Confidence: 0.888663788888889

00:21:29.656 --> 00:21:32.428 one being a Polaris which has been
NOTE Confidence: 0.888663788888889

00:21:32.428 --> 00:21:34.880 hotly debated and discussed in various
NOTE Confidence: 0.888663788888889

00:21:34.880 --> 00:21:37.256 forums after it was presented as
NOTE Confidence: 0.888663788888889

00:21:37.331 --> 00:21:39.413 a late breaking abstract and then

NOTE Confidence: 0.888663788888889
00:21:39.413 --> 00:21:42.114 use of high dose methotrexate to
NOTE Confidence: 0.888663788888889
00:21:42.114 --> 00:21:46.962 reduce CNS relapse which was a big
NOTE Confidence: 0.888663788888889
00:21:46.962 --> 00:21:49.084 retrospective analysis that we'll
NOTE Confidence: 0.888663788888889
00:21:49.084 --> 00:21:50.769 discuss in mantle cell lymphoma.
NOTE Confidence: 0.888663788888889
00:21:50.770 --> 00:21:51.480 I'll discuss.
NOTE Confidence: 0.888663788888889
00:21:51.480 --> 00:21:54.430 From the front line, long term data on MCL.
NOTE Confidence: 0.888663788888889
00:21:54.430 --> 00:21:55.786 One younger trial,
NOTE Confidence: 0.888663788888889
00:21:55.786 --> 00:21:58.950 which is which uses hydro site urban
NOTE Confidence: 0.888663788888889
00:21:59.037 --> 00:22:01.722 containing regimens compared to R
NOTE Confidence: 0.888663788888889
00:22:01.722 --> 00:22:03.966 Chop and then in maintenance setting.
NOTE Confidence: 0.888663788888889
00:22:03.970 --> 00:22:06.580 Use of R-squared which is limited
NOTE Confidence: 0.888663788888889
00:22:06.580 --> 00:22:08.320 with rituximab versus rituximab.
NOTE Confidence: 0.888663788888889
00:22:08.320 --> 00:22:10.798 After first line in elderly patients
NOTE Confidence: 0.888663788888889
00:22:10.798 --> 00:22:13.086 and then in relapsed refractory
NOTE Confidence: 0.888663788888889
00:22:13.086 --> 00:22:15.708 setting glue which is a bite.
NOTE Confidence: 0.888663788888889

00:22:15.708 --> 00:22:17.216 Bispecific T cell engager
NOTE Confidence: 0.888663788888889

00:22:17.216 --> 00:22:19.307 after we take a I failure.
NOTE Confidence: 0.7022962075

00:22:21.850 --> 00:22:23.078 Here are my disclosures.
NOTE Confidence: 0.915625785555556

00:22:25.260 --> 00:22:29.644 So this was probably one of the most
NOTE Confidence: 0.915625785555556

00:22:29.644 --> 00:22:32.540 exciting trials that were, you know,
NOTE Confidence: 0.915625785555556

00:22:32.540 --> 00:22:35.424 discussed and presented at ASH 2021,
NOTE Confidence: 0.915625785555556

00:22:35.424 --> 00:22:37.236 which potentially changes
NOTE Confidence: 0.915625785555556

00:22:37.236 --> 00:22:40.256 our frontline care in DLBCL.
NOTE Confidence: 0.915625785555556

00:22:40.260 --> 00:22:42.740 And hence I would like to discuss this
NOTE Confidence: 0.915625785555556

00:22:42.740 --> 00:22:45.197 so there's a bullet is alive with Odin,
NOTE Confidence: 0.915625785555556

00:22:45.200 --> 00:22:48.386 is an antibody drug conjugate which
NOTE Confidence: 0.915625785555556

00:22:48.386 --> 00:22:52.115 targets CD79-B and eventually leads to
NOTE Confidence: 0.915625785555556

00:22:52.115 --> 00:22:55.310 microtubule disruption and epic ptosis.
NOTE Confidence: 0.915625785555556

00:22:55.310 --> 00:22:57.030 And you know it was.
NOTE Confidence: 0.915625785555556

00:22:57.030 --> 00:22:59.838 It has been extensively studied and
NOTE Confidence: 0.915625785555556

00:22:59.838 --> 00:23:02.160 now approved in combination with.

NOTE Confidence: 0.915625785555556
00:23:02.160 --> 00:23:05.710 In the relapsed refractory setting.
NOTE Confidence: 0.915625785555556
00:23:05.710 --> 00:23:09.660 So the researchers here studied
NOTE Confidence: 0.915625785555556
00:23:09.660 --> 00:23:12.370 patients who were previously untreated,
NOTE Confidence: 0.915625785555556
00:23:12.370 --> 00:23:13.842 had done previously untreated
NOTE Confidence: 0.915625785555556
00:23:13.842 --> 00:23:16.050 DLBCL age 18 to 8 years.
NOTE Confidence: 0.915625785555556
00:23:16.050 --> 00:23:21.530 IPI score of two to 5 = 0 to 2.
NOTE Confidence: 0.915625785555556
00:23:21.530 --> 00:23:23.408 With stratification factors
NOTE Confidence: 0.915625785555556
00:23:23.408 --> 00:23:25.286 as mentioned here.
NOTE Confidence: 0.915625785555556
00:23:25.290 --> 00:23:27.310 Randomize one to one between
NOTE Confidence: 0.915625785555556
00:23:27.310 --> 00:23:29.330 Polar archip versus R chop.
NOTE Confidence: 0.915625785555556
00:23:29.330 --> 00:23:30.705 So when Christine was swapped
NOTE Confidence: 0.915625785555556
00:23:30.705 --> 00:23:33.800 with a political map, dwtin.
NOTE Confidence: 0.915625785555556
00:23:33.800 --> 00:23:35.776 And it's important to note that it is
NOTE Confidence: 0.915625785555556
00:23:35.776 --> 00:23:37.360 a randomized double blinded study,
NOTE Confidence: 0.915625785555556
00:23:37.360 --> 00:23:40.258 so the investigators or patients had no,
NOTE Confidence: 0.915625785555556

00:23:40.260 --> 00:23:43.158 I did not know what therapy
NOTE Confidence: 0.915625785555556

00:23:43.158 --> 00:23:44.607 they were receiving.
NOTE Confidence: 0.915625785555556

00:23:44.610 --> 00:23:46.075 And this was followed by
NOTE Confidence: 0.915625785555556

00:23:46.075 --> 00:23:47.247 two cycles of rituximab.
NOTE Confidence: 0.915625785555556

00:23:47.250 --> 00:23:51.090 This was mainly to satisfy European
NOTE Confidence: 0.915625785555556

00:23:51.090 --> 00:23:54.240 regulatory requirements as eight cycles
NOTE Confidence: 0.915625785555556

00:23:54.240 --> 00:23:57.698 of therapy is a standard in Europe.
NOTE Confidence: 0.915625785555556

00:23:57.700 --> 00:23:59.148 The primary endpoint was
NOTE Confidence: 0.915625785555556

00:23:59.148 --> 00:24:00.234 progression free survival,
NOTE Confidence: 0.915625785555556

00:24:00.240 --> 00:24:01.860 which was investigator assessed.
NOTE Confidence: 0.915625785555556

00:24:01.860 --> 00:24:03.885 Secondary endpoints are listed here.
NOTE Confidence: 0.828113313

00:24:06.630 --> 00:24:08.568 And these were the demographic and
NOTE Confidence: 0.828113313

00:24:08.568 --> 00:24:09.860 clinical characteristics at baseline,
NOTE Confidence: 0.828113313

00:24:09.860 --> 00:24:13.304 so you know it's very well balanced.
NOTE Confidence: 0.828113313

00:24:13.310 --> 00:24:15.662 The important things to note here
NOTE Confidence: 0.828113313

00:24:15.662 --> 00:24:18.212 are there are 10% of patients

NOTE Confidence: 0.828113313
00:24:18.212 --> 00:24:21.158 with early stage disease and 90%
NOTE Confidence: 0.828113313
00:24:21.160 --> 00:24:23.788 with stage three or four disease,
NOTE Confidence: 0.828113313
00:24:23.790 --> 00:24:27.549 and IPI score of two was in
NOTE Confidence: 0.828113313
00:24:27.549 --> 00:24:29.636 approximately 38% of patients
NOTE Confidence: 0.828113313
00:24:29.636 --> 00:24:32.654 versus 62% were three to five,
NOTE Confidence: 0.828113313
00:24:32.660 --> 00:24:36.524 and it was well balanced between ABC and.
NOTE Confidence: 0.828113313
00:24:36.530 --> 00:24:37.852 Subtype, interestingly,
NOTE Confidence: 0.828113313
00:24:37.852 --> 00:24:41.157 there were double expressor lymphomas
NOTE Confidence: 0.828113313
00:24:41.157 --> 00:24:43.140 quite heavily represented,
NOTE Confidence: 0.828113313
00:24:43.140 --> 00:24:46.080 38% versus 41%,
NOTE Confidence: 0.828113313
00:24:46.080 --> 00:24:49.510 and double hit lymphoma or triple in
NOTE Confidence: 0.828113313
00:24:49.510 --> 00:24:52.678 lymphomas were 8% and 6% respectively.
NOTE Confidence: 0.786806552
00:24:54.940 --> 00:24:57.280 So these are the curves,
NOTE Confidence: 0.786806552
00:24:57.280 --> 00:25:00.244 the number one being investigated as
NOTE Confidence: 0.786806552
00:25:00.244 --> 00:25:02.220 assessed progression free survival,
NOTE Confidence: 0.786806552

00:25:02.220 --> 00:25:05.476 which was the primary endpoint of this trial,
NOTE Confidence: 0.786806552

00:25:05.480 --> 00:25:09.200 and the hazard ratio was of 0.73 not
NOTE Confidence: 0.786806552

00:25:09.200 --> 00:25:12.350 crossing one with P value of 0.02,
NOTE Confidence: 0.786806552

00:25:12.350 --> 00:25:15.110 showing statistical significance of
NOTE Confidence: 0.786806552

00:25:15.110 --> 00:25:19.669 polar chip in comparison to our chalk.
NOTE Confidence: 0.786806552

00:25:19.670 --> 00:25:22.510 If you if you see here the overall
NOTE Confidence: 0.786806552

00:25:22.510 --> 00:25:25.352 survival then you clearly there is no
NOTE Confidence: 0.786806552

00:25:25.352 --> 00:25:28.250 overall survival benefit at at at the
NOTE Confidence: 0.786806552

00:25:28.342 --> 00:25:31.382 short term follow-up so far with a P
NOTE Confidence: 0.786806552

00:25:31.382 --> 00:25:34.340 value of 0.75 and hazard ratio of 0.94.
NOTE Confidence: 0.860221215333333

00:25:36.830 --> 00:25:39.250 Interestingly, this is is assessment
NOTE Confidence: 0.860221215333333

00:25:39.250 --> 00:25:41.670 of patients who received subsequent
NOTE Confidence: 0.860221215333333

00:25:41.740 --> 00:25:44.430 treatments after this frontline therapy.
NOTE Confidence: 0.860221215333333

00:25:44.430 --> 00:25:46.365 And clearly if you count
NOTE Confidence: 0.860221215333333

00:25:46.365 --> 00:25:47.913 any modality of treatment,
NOTE Confidence: 0.860221215333333

00:25:47.920 --> 00:25:50.485 then our top armed patients

NOTE Confidence: 0.860221215333333
00:25:50.485 --> 00:25:52.024 got substantially more.
NOTE Confidence: 0.860221215333333
00:25:52.030 --> 00:25:54.870 30% of patients got received.
NOTE Confidence: 0.860221215333333
00:25:54.870 --> 00:25:56.910 Subsequent treatments versus
NOTE Confidence: 0.860221215333333
00:25:56.910 --> 00:25:58.898 only 22.5% in polar artship.
NOTE Confidence: 0.89812805
00:26:02.230 --> 00:26:04.141 This is the subgroup analysis and I
NOTE Confidence: 0.89812805
00:26:04.141 --> 00:26:06.129 would like to draw your attention,
NOTE Confidence: 0.89812805
00:26:06.130 --> 00:26:08.994 although we would you know caution in making
NOTE Confidence: 0.89812805
00:26:08.994 --> 00:26:13.820 any too strong of conclusions here, but.
NOTE Confidence: 0.89812805
00:26:13.820 --> 00:26:15.842 Monkey disease if it was absent
NOTE Confidence: 0.89812805
00:26:15.842 --> 00:26:18.296 at polar Chip, showed more
NOTE Confidence: 0.89812805
00:26:18.296 --> 00:26:20.450 statistically significant advantage.
NOTE Confidence: 0.89812805
00:26:20.450 --> 00:26:24.440 ABC seller Origin, you know,
NOTE Confidence: 0.89812805
00:26:24.440 --> 00:26:28.416 pull our chip bit better in that
NOTE Confidence: 0.89812805
00:26:28.416 --> 00:26:30.994 and IPI score of three to five
NOTE Confidence: 0.89812805
00:26:30.994 --> 00:26:33.151 versus 2 polar chips seem to
NOTE Confidence: 0.89812805

00:26:33.151 --> 00:26:35.026 do better in those subgroups.
NOTE Confidence: 0.843307762

00:26:38.720 --> 00:26:39.680 Common adverse events.
NOTE Confidence: 0.843307762

00:26:39.680 --> 00:26:42.036 This is, I think, a very important slide,
NOTE Confidence: 0.843307762

00:26:42.040 --> 00:26:44.854 because this really tells us that the
NOTE Confidence: 0.843307762

00:26:44.854 --> 00:26:47.352 double blinded portion of the study
NOTE Confidence: 0.843307762

00:26:47.352 --> 00:26:49.392 worked well because it's identical
NOTE Confidence: 0.843307762

00:26:49.392 --> 00:26:51.488 between polar chip and our chop,
NOTE Confidence: 0.843307762

00:26:51.490 --> 00:26:53.498 including peripheral neuropathy incidents.
NOTE Confidence: 0.843307762

00:26:53.498 --> 00:26:56.510 There was slight higher rate of
NOTE Confidence: 0.843307762

00:26:56.582 --> 00:26:58.290 higher grade febrile neutropenia
NOTE Confidence: 0.843307762

00:26:58.290 --> 00:27:00.852 in polar archip versus R chop,
NOTE Confidence: 0.843307762

00:27:00.860 --> 00:27:02.354 but the rest of the side
NOTE Confidence: 0.843307762

00:27:02.354 --> 00:27:03.350 effects are pretty compatible.
NOTE Confidence: 0.878186221904762

00:27:05.500 --> 00:27:07.932 So the way I see this trial is
NOTE Confidence: 0.878186221904762

00:27:07.932 --> 00:27:10.296 very nicely depicted in this figure
NOTE Confidence: 0.878186221904762

00:27:10.296 --> 00:27:12.816 from a cancer cell paper published

NOTE Confidence: 0.878186221904762
00:27:12.890 --> 00:27:15.925 recently by Doctor Chu is essentially
NOTE Confidence: 0.878186221904762
00:27:15.925 --> 00:27:19.517 a patients who are at have higher
NOTE Confidence: 0.878186221904762
00:27:19.517 --> 00:27:21.518 IPI score in the current setting.
NOTE Confidence: 0.878186221904762
00:27:21.518 --> 00:27:23.443 They would get our chop and when they
NOTE Confidence: 0.878186221904762
00:27:23.443 --> 00:27:25.115 fail they would be in this pool to
NOTE Confidence: 0.878186221904762
00:27:25.167 --> 00:27:26.617 get autologous stem cell transplant
NOTE Confidence: 0.878186221904762
00:27:26.617 --> 00:27:28.864 or they would have failed and they
NOTE Confidence: 0.878186221904762
00:27:28.864 --> 00:27:31.246 would have gotten a salvage regimens.
NOTE Confidence: 0.878186221904762
00:27:31.250 --> 00:27:33.574 In the future we would re stratify
NOTE Confidence: 0.878186221904762
00:27:33.574 --> 00:27:35.749 them based on their IPI score.
NOTE Confidence: 0.878186221904762
00:27:35.750 --> 00:27:37.748 I remember that 225 was the
NOTE Confidence: 0.878186221904762
00:27:37.748 --> 00:27:38.414 inclusion criteria,
NOTE Confidence: 0.878186221904762
00:27:38.420 --> 00:27:40.415 subgroup was for the three to five,
NOTE Confidence: 0.878186221904762
00:27:40.420 --> 00:27:42.175 showing more advantage,
NOTE Confidence: 0.878186221904762
00:27:42.175 --> 00:27:45.685 but all you know the inclusion
NOTE Confidence: 0.878186221904762

00:27:45.685 --> 00:27:47.848 criteria was two to five.
NOTE Confidence: 0.878186221904762

00:27:47.850 --> 00:27:49.986 And then you would basically give
NOTE Confidence: 0.878186221904762

00:27:49.986 --> 00:27:51.870 our choppin lower IPI score.
NOTE Confidence: 0.878186221904762

00:27:51.870 --> 00:27:54.766 Patients and polar ship in the higher ones,
NOTE Confidence: 0.878186221904762

00:27:54.770 --> 00:27:57.185 and then you would have less patience.
NOTE Confidence: 0.878186221904762

00:27:57.190 --> 00:27:59.080 Who would relapse and the ones
NOTE Confidence: 0.878186221904762

00:27:59.080 --> 00:28:00.025 who would relapse.
NOTE Confidence: 0.878186221904762

00:28:00.030 --> 00:28:01.848 You have now options of autologous
NOTE Confidence: 0.878186221904762

00:28:01.848 --> 00:28:03.423 stem cell transplant if they
NOTE Confidence: 0.878186221904762

00:28:03.423 --> 00:28:04.948 have relapsed after 12 months,
NOTE Confidence: 0.878186221904762

00:28:04.950 --> 00:28:08.262 or they have achieved complete remission
NOTE Confidence: 0.878186221904762

00:28:08.262 --> 00:28:11.510 from salvage regimen or car T cell therapy,
NOTE Confidence: 0.878186221904762

00:28:11.510 --> 00:28:13.246 and if they fail then to move
NOTE Confidence: 0.878186221904762

00:28:13.246 --> 00:28:14.520 on to salvage regimen.
NOTE Confidence: 0.878186221904762

00:28:14.520 --> 00:28:16.711 So this way we hope that we
NOTE Confidence: 0.878186221904762

00:28:16.711 --> 00:28:17.650 have less patience.

NOTE Confidence: 0.878186221904762
00:28:17.650 --> 00:28:19.880 In this pool to treat.
NOTE Confidence: 0.824315556842105
00:28:23.600 --> 00:28:25.861 So my final thoughts on the politics
NOTE Confidence: 0.824315556842105
00:28:25.861 --> 00:28:28.946 trial is that PFS benefit from a well
NOTE Confidence: 0.824315556842105
00:28:28.946 --> 00:28:30.582 designed randomized control trial
NOTE Confidence: 0.824315556842105
00:28:30.590 --> 00:28:33.390 in this population is meaningful.
NOTE Confidence: 0.824315556842105
00:28:33.390 --> 00:28:35.654 Regulatory approval is pending.
NOTE Confidence: 0.824315556842105
00:28:35.654 --> 00:28:38.085 Currently, long term data will guide
NOTE Confidence: 0.824315556842105
00:28:38.085 --> 00:28:40.518 further use subgroup analysis is only
NOTE Confidence: 0.824315556842105
00:28:40.518 --> 00:28:42.998 hypothesis generating no known biological
NOTE Confidence: 0.824315556842105
00:28:42.998 --> 00:28:45.499 rationale for higher responses in ABC.
NOTE Confidence: 0.824315556842105
00:28:45.500 --> 00:28:47.680 DLBCL is known so far.
NOTE Confidence: 0.824315556842105
00:28:47.680 --> 00:28:49.730 What will be the role of polit ISM and we
NOTE Confidence: 0.824315556842105
00:28:49.780 --> 00:28:51.676 wrote in and relaxed refractory DLBCL.
NOTE Confidence: 0.824315556842105
00:28:51.680 --> 00:28:54.830 Uh, because we all use polar,
NOTE Confidence: 0.824315556842105
00:28:54.830 --> 00:28:56.782 quite commonly in relapsed
NOTE Confidence: 0.824315556842105

00:28:56.782 --> 00:28:58.556 refractory setting as salvage,
NOTE Confidence: 0.824315556842105

00:28:58.556 --> 00:29:01.942 and that is going to become a problem
NOTE Confidence: 0.824315556842105

00:29:01.942 --> 00:29:04.726 once polatuzumab wrote in moves frontline.
NOTE Confidence: 0.824315556842105

00:29:04.730 --> 00:29:07.068 The good news is that we have
NOTE Confidence: 0.824315556842105

00:29:07.068 --> 00:29:08.737 other approved therapies like Tafel
NOTE Confidence: 0.824315556842105

00:29:08.737 --> 00:29:10.543 in and Lanka struck some AB,
NOTE Confidence: 0.824315556842105

00:29:10.550 --> 00:29:13.034 so hopefully we'll have more approvals
NOTE Confidence: 0.824315556842105

00:29:13.034 --> 00:29:16.843 in the future and we can expand our
NOTE Confidence: 0.824315556842105

00:29:16.843 --> 00:29:18.397 relapsed refractory repertoire.
NOTE Confidence: 0.824315556842105

00:29:18.400 --> 00:29:20.540 While the differences are statistically
NOTE Confidence: 0.824315556842105

00:29:20.540 --> 00:29:21.824 and clinically meaningful,
NOTE Confidence: 0.824315556842105

00:29:21.830 --> 00:29:23.780 this is not a game changer.
NOTE Confidence: 0.824315556842105

00:29:23.780 --> 00:29:25.635 Other class of drugs like bites and
NOTE Confidence: 0.824315556842105

00:29:25.635 --> 00:29:27.841 car T cells should and are being
NOTE Confidence: 0.824315556842105

00:29:27.841 --> 00:29:28.855 studied in frontline,
NOTE Confidence: 0.824315556842105

00:29:28.860 --> 00:29:31.620 especially in high risk disease.

NOTE Confidence: 0.824315556842105
00:29:31.620 --> 00:29:33.560 Financial toxicity is real and
NOTE Confidence: 0.824315556842105
00:29:33.560 --> 00:29:35.500 should be discussed with patients
NOTE Confidence: 0.824315556842105
00:29:35.564 --> 00:29:37.016 on a case by case basis.
NOTE Confidence: 0.780394385833333
00:29:39.840 --> 00:29:42.773 2nd is hydro methotrexate is not associated
NOTE Confidence: 0.780394385833333
00:29:42.773 --> 00:29:45.722 with reduction in CNS relapse in patients
NOTE Confidence: 0.780394385833333
00:29:45.722 --> 00:29:48.152 with aggressive B cell lymphoma and
NOTE Confidence: 0.780394385833333
00:29:48.226 --> 00:29:50.698 international retrospective study of
NOTE Confidence: 0.780394385833333
00:29:50.700 --> 00:29:55.656 2300 patients presented by Doctor Lewis.
NOTE Confidence: 0.780394385833333
00:29:55.660 --> 00:29:58.315 So we know that CNS IPI score is helpful
NOTE Confidence: 0.780394385833333
00:29:58.315 --> 00:30:00.698 in knowing what kind of patients are
NOTE Confidence: 0.780394385833333
00:30:00.698 --> 00:30:03.268 going to have a CNS relapse at are
NOTE Confidence: 0.780394385833333
00:30:03.268 --> 00:30:05.677 at a higher risk of CNS relapse.
NOTE Confidence: 0.780394385833333
00:30:05.677 --> 00:30:10.416 But overall patients with those high risk
NOTE Confidence: 0.780394385833333
00:30:10.416 --> 00:30:14.478 features they fare poorly and much needs
NOTE Confidence: 0.780394385833333
00:30:14.478 --> 00:30:17.926 to be done to prevent these relapses,
NOTE Confidence: 0.780394385833333

00:30:17.926 --> 00:30:21.433 so there is no consensus on what CNS
NOTE Confidence: 0.780394385833333

00:30:21.433 --> 00:30:23.548 directed prophylactic therapy should be
NOTE Confidence: 0.780394385833333

00:30:23.548 --> 00:30:26.194 given and how it should be incorporated.
NOTE Confidence: 0.780394385833333

00:30:26.200 --> 00:30:30.190 Into the systemic therapy backbone.
NOTE Confidence: 0.780394385833333

00:30:30.190 --> 00:30:31.846 Many centers, including Yale,
NOTE Confidence: 0.780394385833333

00:30:31.846 --> 00:30:34.330 we we have used hydro methotrexate,
NOTE Confidence: 0.780394385833333

00:30:34.330 --> 00:30:36.502 which we hope mitigate CNS risk
NOTE Confidence: 0.780394385833333

00:30:36.502 --> 00:30:38.510 based on some retrospective studies.
NOTE Confidence: 0.780394385833333

00:30:38.510 --> 00:30:41.058 In the past there is no prospective
NOTE Confidence: 0.780394385833333

00:30:41.058 --> 00:30:43.269 data to guide our treatment.
NOTE Confidence: 0.780394385833333

00:30:43.270 --> 00:30:45.130 So this eligibility criteria was
NOTE Confidence: 0.780394385833333

00:30:45.130 --> 00:30:47.749 patients with CNS IP S score of
NOTE Confidence: 0.780394385833333

00:30:47.749 --> 00:30:49.825 426 high grade B cell lymphomas,
NOTE Confidence: 0.780394385833333

00:30:49.830 --> 00:30:52.182 where we automatically give
NOTE Confidence: 0.780394385833333

00:30:52.182 --> 00:30:53.946 CNS prophylaxis therapy,
NOTE Confidence: 0.780394385833333

00:30:53.950 --> 00:30:57.958 primary breast or testicular DLBCL with the

NOTE Confidence: 0.780394385833333
00:30:57.958 --> 00:31:01.136 rest of the inclusion criteria shown here.
NOTE Confidence: 0.780394385833333
00:31:01.140 --> 00:31:03.564 Including exclusion being CNS
NOTE Confidence: 0.780394385833333
00:31:03.564 --> 00:31:06.594 involvement by lymphoma at diagnosis.
NOTE Confidence: 0.745650676
00:31:08.660 --> 00:31:12.600 2300 patients were enrolled and.
NOTE Confidence: 0.745650676
00:31:12.600 --> 00:31:14.550 Almost 2000 to 1800 patients did
NOTE Confidence: 0.745650676
00:31:14.550 --> 00:31:16.354 not get high dose methotrexate
NOTE Confidence: 0.745650676
00:31:16.354 --> 00:31:18.970 versus 400 patients got high dose
NOTE Confidence: 0.745650676
00:31:18.970 --> 00:31:21.318 methotrexate and out of those patients
NOTE Confidence: 0.745650676
00:31:21.318 --> 00:31:23.126 who got high dose methotrexate,
NOTE Confidence: 0.745650676
00:31:23.126 --> 00:31:25.656 CNS relapse was observed in
NOTE Confidence: 0.745650676
00:31:25.656 --> 00:31:28.010 31 patients which is 8%.
NOTE Confidence: 0.79133678
00:31:30.750 --> 00:31:34.230 Just to draw your attention to
NOTE Confidence: 0.79133678
00:31:34.230 --> 00:31:37.469 the fact that really it was,
NOTE Confidence: 0.79133678
00:31:37.470 --> 00:31:39.648 you know, but it percentage wise,
NOTE Confidence: 0.79133678
00:31:39.650 --> 00:31:43.904 well balanced study including the E,
NOTE Confidence: 0.79133678

00:31:43.904 --> 00:31:46.536 COG and B symptoms.
NOTE Confidence: 0.79133678

00:31:46.540 --> 00:31:48.025 And external sites,
NOTE Confidence: 0.79133678

00:31:48.025 --> 00:31:50.995 which was of course heavily heavily
NOTE Confidence: 0.79133678

00:31:50.995 --> 00:31:53.930 represented in high dose methotrexate group.
NOTE Confidence: 0.79133678

00:31:53.930 --> 00:31:55.810 Here I would like to draw your attention
NOTE Confidence: 0.79133678

00:31:55.810 --> 00:31:57.688 to the high risk extranodal sites.
NOTE Confidence: 0.79133678

00:31:57.690 --> 00:32:00.174 So clearly we have more representation
NOTE Confidence: 0.79133678

00:32:00.174 --> 00:32:03.121 of those patients in the high dose
NOTE Confidence: 0.79133678

00:32:03.121 --> 00:32:05.563 methotrexate group as we would have
NOTE Confidence: 0.79133678

00:32:05.563 --> 00:32:07.674 expected and in as you go higher
NOTE Confidence: 0.79133678

00:32:07.674 --> 00:32:10.120 up in the number of external sites
NOTE Confidence: 0.79133678

00:32:10.120 --> 00:32:12.180 you have high representation in
NOTE Confidence: 0.79133678

00:32:12.180 --> 00:32:14.409 the high dose methotrexate group
NOTE Confidence: 0.79133678

00:32:14.409 --> 00:32:16.629 as we would have expected.
NOTE Confidence: 0.79133678

00:32:16.630 --> 00:32:17.860 These these are the results,
NOTE Confidence: 0.79133678

00:32:17.860 --> 00:32:19.640 so in all patients,

NOTE Confidence: 0.79133678

00:32:19.640 --> 00:32:21.865 cumulative incidence of CNS relapse

NOTE Confidence: 0.79133678

00:32:21.865 --> 00:32:24.168 was not statistically significant

NOTE Confidence: 0.79133678

00:32:24.168 --> 00:32:26.540 between these two groups.

NOTE Confidence: 0.79133678

00:32:26.540 --> 00:32:29.277 It shows 9.2% in Hydros method exit

NOTE Confidence: 0.79133678

00:32:29.277 --> 00:32:32.674 group and eight point 1% in in patients

NOTE Confidence: 0.79133678

00:32:32.674 --> 00:32:36.230 who did not get high dose methotrexate.

NOTE Confidence: 0.79133678

00:32:36.230 --> 00:32:38.030 The similar results hold true

NOTE Confidence: 0.79133678

00:32:38.030 --> 00:32:39.830 for patients who achieved CR,

NOTE Confidence: 0.79133678

00:32:39.830 --> 00:32:42.038 so this is a subgroup analysis.

NOTE Confidence: 0.81215900125

00:32:46.310 --> 00:32:48.334 And this is the site of CNS relapse,

NOTE Confidence: 0.81215900125

00:32:48.340 --> 00:32:49.960 which I thought was very interesting.

NOTE Confidence: 0.81215900125

00:32:49.960 --> 00:32:52.585 So patients who did get high dose

NOTE Confidence: 0.81215900125

00:32:52.585 --> 00:32:54.571 methotrexate they saw less of

NOTE Confidence: 0.81215900125

00:32:54.571 --> 00:32:56.520 parent kaimal relapse versus they

NOTE Confidence: 0.81215900125

00:32:56.520 --> 00:32:58.040 saw higher leptomeningeal relapse.

NOTE Confidence: 0.81215900125

00:32:58.040 --> 00:32:59.540 So that brings into question
NOTE Confidence: 0.81215900125

00:32:59.540 --> 00:33:01.547 whether a dual strategy of high
NOTE Confidence: 0.81215900125

00:33:01.547 --> 00:33:03.343 dose methotrexate with intrathecal
NOTE Confidence: 0.81215900125

00:33:03.343 --> 00:33:05.139 methotrexate would be appropriate.
NOTE Confidence: 0.81215900125

00:33:05.140 --> 00:33:08.530 Although there is no data to support that.
NOTE Confidence: 0.926234849285714

00:33:11.060 --> 00:33:13.265 And then the group describes
NOTE Confidence: 0.926234849285714

00:33:13.265 --> 00:33:15.029 multiple subgroup analysis based
NOTE Confidence: 0.926234849285714

00:33:15.029 --> 00:33:17.269 on number of external sites.
NOTE Confidence: 0.926234849285714

00:33:17.270 --> 00:33:19.474 Specific external site involvement,
NOTE Confidence: 0.926234849285714

00:33:19.474 --> 00:33:23.932 CNS IPI score and the dosage of high dose
NOTE Confidence: 0.926234849285714

00:33:23.932 --> 00:33:25.756 methotrexate and so on and so forth.
NOTE Confidence: 0.926234849285714

00:33:25.760 --> 00:33:28.308 But none of these subgroup analysis showed
NOTE Confidence: 0.926234849285714

00:33:28.308 --> 00:33:30.420 any statistical or clinically meaningful
NOTE Confidence: 0.926234849285714

00:33:30.420 --> 00:33:32.810 difference between the two groups.
NOTE Confidence: 0.909237501111111

00:33:39.030 --> 00:33:40.842 So in conclusion, in the largest
NOTE Confidence: 0.909237501111111

00:33:40.842 --> 00:33:42.116 study to date, investigating

NOTE Confidence: 0.9092375011111111
00:33:42.116 --> 00:33:43.946 efficacy of high dose methotrexate.
NOTE Confidence: 0.578636815
00:33:46.070 --> 00:33:48.170 In reducing CNS relapse in high risk
NOTE Confidence: 0.578636815
00:33:48.170 --> 00:33:50.195 patients, high dose methotrexate was not
NOTE Confidence: 0.578636815
00:33:50.195 --> 00:33:52.420 associated with reduction in CNS relapse.
NOTE Confidence: 0.578636815
00:33:52.420 --> 00:33:54.210 In overall, for patients within
NOTE Confidence: 0.578636815
00:33:54.210 --> 00:33:57.100 CR or in any high risk subgroup.
NOTE Confidence: 0.798993183909091
00:34:00.490 --> 00:34:03.682 Up next I would like to move to
NOTE Confidence: 0.798993183909091
00:34:03.682 --> 00:34:06.208 mantle cell lymphoma and discuss
NOTE Confidence: 0.798993183909091
00:34:06.208 --> 00:34:08.872 addition of hydro site therapy into
NOTE Confidence: 0.798993183909091
00:34:08.872 --> 00:34:10.225 immunochemotherapy before autologous
NOTE Confidence: 0.798993183909091
00:34:10.225 --> 00:34:12.205 stem cell transplantation in patients
NOTE Confidence: 0.798993183909091
00:34:12.205 --> 00:34:14.799 aged 65 years or younger with MCL
NOTE Confidence: 0.798993183909091
00:34:14.799 --> 00:34:17.011 known as the MCL one younger study.
NOTE Confidence: 0.796857616666667
00:34:19.240 --> 00:34:21.598 497 patients were randomized between control,
NOTE Confidence: 0.796857616666667
00:34:21.600 --> 00:34:23.910 which is our chop and experimental group
NOTE Confidence: 0.796857616666667

00:34:23.910 --> 00:34:26.587 being our chop alternating with our dehab,
NOTE Confidence: 0.796857616666667

00:34:26.590 --> 00:34:28.390 which can contain Sitara green.
NOTE Confidence: 0.672028358142857

00:34:30.680 --> 00:34:33.333 The results in which were initially 1st
NOTE Confidence: 0.672028358142857

00:34:33.333 --> 00:34:35.800 results published in 2016 are shown here,
NOTE Confidence: 0.672028358142857

00:34:35.800 --> 00:34:37.186 which I'm going to skip over.
NOTE Confidence: 0.8688862075

00:34:39.300 --> 00:34:43.940 The updated results from 2021 are shown here,
NOTE Confidence: 0.8688862075

00:34:43.940 --> 00:34:46.313 so you see that there is significant
NOTE Confidence: 0.8688862075

00:34:46.313 --> 00:34:48.149 difference between the site urban
NOTE Confidence: 0.8688862075

00:34:48.149 --> 00:34:50.039 containing regimen versus our chop.
NOTE Confidence: 0.8688862075

00:34:50.040 --> 00:34:52.740 With trying to treatment failure
NOTE Confidence: 0.8688862075

00:34:52.740 --> 00:34:54.558 8.4 years in our dehab arm
NOTE Confidence: 0.8688862075

00:34:54.558 --> 00:34:56.419 versus four years in our chop.
NOTE Confidence: 0.569701485714286

00:34:58.510 --> 00:35:03.046 Similar results hold true for in PFS,
NOTE Confidence: 0.569701485714286

00:35:03.050 --> 00:35:07.175 looking at from randomization from end of
NOTE Confidence: 0.569701485714286

00:35:07.175 --> 00:35:10.420 induction and from a stem cell transplant
NOTE Confidence: 0.569701485714286

00:35:10.420 --> 00:35:13.087 and you know this is very striking.

NOTE Confidence: 0.569701485714286
00:35:13.090 --> 00:35:15.771 To note that eight years was the
NOTE Confidence: 0.569701485714286
00:35:15.771 --> 00:35:19.009 median PFS in our chat party help arm,
NOTE Confidence: 0.569701485714286
00:35:19.010 --> 00:35:22.138 which is quite significant.
NOTE Confidence: 0.77298903
00:35:24.240 --> 00:35:27.082 Overall survival when you look at all
NOTE Confidence: 0.77298903
00:35:27.082 --> 00:35:29.778 comes and intention to treat population,
NOTE Confidence: 0.77298903
00:35:29.780 --> 00:35:31.792 there was no statistically
NOTE Confidence: 0.77298903
00:35:31.792 --> 00:35:32.798 significant difference.
NOTE Confidence: 0.77298903
00:35:32.800 --> 00:35:35.166 But if you stratify them by nippy
NOTE Confidence: 0.77298903
00:35:35.166 --> 00:35:37.331 then there was statistical least
NOTE Confidence: 0.77298903
00:35:37.331 --> 00:35:39.479 significant difference with hazard
NOTE Confidence: 0.77298903
00:35:39.479 --> 00:35:42.730 ratio of .74 not crossing the midline.
NOTE Confidence: 0.736200225833333
00:35:44.800 --> 00:35:48.104 And these are the highest highest subgroup
NOTE Confidence: 0.736200225833333
00:35:48.104 --> 00:35:50.500 stratification curves for all survival.
NOTE Confidence: 0.736200225833333
00:35:50.500 --> 00:35:51.980 So here you have high
NOTE Confidence: 0.736200225833333
00:35:51.980 --> 00:35:53.460 risk in defined by high,
NOTE Confidence: 0.736200225833333

00:35:53.460 --> 00:35:55.240 intermediate or high MIDI score.
NOTE Confidence: 0.736200225833333

00:35:55.240 --> 00:35:59.937 High High P53, MHC or BLASTOID variant,
NOTE Confidence: 0.736200225833333

00:35:59.940 --> 00:36:02.886 and versus low risk where you
NOTE Confidence: 0.736200225833333

00:36:02.886 --> 00:36:04.850 have no statistically significant
NOTE Confidence: 0.736200225833333

00:36:04.935 --> 00:36:07.510 difference between the two parks.
NOTE Confidence: 0.736200225833333

00:36:07.510 --> 00:36:09.848 So conclusions are that hydro site have
NOTE Confidence: 0.736200225833333

00:36:09.848 --> 00:36:11.620 been containing induction and autologous
NOTE Confidence: 0.736200225833333

00:36:11.620 --> 00:36:13.415 stem cell transplant achieves 60%.
NOTE Confidence: 0.87940361375

00:36:15.970 --> 00:36:18.480 60% survival at 10 years
NOTE Confidence: 0.87940361375

00:36:18.480 --> 00:36:19.986 with acceptable toxicity.
NOTE Confidence: 0.87940361375

00:36:19.990 --> 00:36:21.525 Benefits of hydro cytarabine in
NOTE Confidence: 0.87940361375

00:36:21.525 --> 00:36:23.640 high and low low risk patients.
NOTE Confidence: 0.87940361375

00:36:23.640 --> 00:36:26.164 Was observed was significantly
NOTE Confidence: 0.87940361375

00:36:26.164 --> 00:36:29.154 improved when adjusted to 67.
NOTE Confidence: 0.87940361375

00:36:29.154 --> 00:36:31.010 Open questions still remain.
NOTE Confidence: 0.87940361375

00:36:31.010 --> 00:36:33.240 Salvage treatment in art shop

NOTE Confidence: 0.87940361375

00:36:33.240 --> 00:36:35.822 patients and avoidance of TBI

NOTE Confidence: 0.87940361375

00:36:35.822 --> 00:36:38.487 may reduce rates of secondary

NOTE Confidence: 0.87940361375

00:36:38.487 --> 00:36:40.458 malignancies in in both arms.

NOTE Confidence: 0.667661556

00:36:43.690 --> 00:36:47.070 Next, I'll quickly discuss rituximab,

NOTE Confidence: 0.667661556

00:36:47.070 --> 00:36:49.006 a little mild maintenance,

NOTE Confidence: 0.667661556

00:36:49.006 --> 00:36:51.426 superior to rituximab maintenance after

NOTE Confidence: 0.667661556

00:36:51.426 --> 00:36:53.630 Firstline Immunochemotherapy in MCL,

NOTE Confidence: 0.667661556

00:36:53.630 --> 00:36:56.010 which was the R-squared,

NOTE Confidence: 0.667661556

00:36:56.010 --> 00:36:58.950 elderly Merle clinical trial. Uhm?

NOTE Confidence: 0.7044647775

00:37:01.660 --> 00:37:04.232 And, uh, another abstract

NOTE Confidence: 0.7044647775

00:37:04.232 --> 00:37:06.804 from the same trial.

NOTE Confidence: 0.7044647775

00:37:06.810 --> 00:37:09.684 Looking at MRD and its prognostic

NOTE Confidence: 0.7044647775

00:37:09.684 --> 00:37:12.260 value in the same trial.

NOTE Confidence: 0.7044647775

00:37:12.260 --> 00:37:16.070 So this trial randomized 620 patients

NOTE Confidence: 0.7044647775

00:37:16.070 --> 00:37:19.646 between control arm where 312 patients

NOTE Confidence: 0.7044647775

00:37:19.646 --> 00:37:22.236 got our chopped versus cytarabine
NOTE Confidence: 0.7044647775

00:37:22.236 --> 00:37:25.037 containing regimen which incorporated art
NOTE Confidence: 0.7044647775

00:37:25.037 --> 00:37:27.957 shop alternating with hydro cytarabine.
NOTE Confidence: 0.7044647775

00:37:27.960 --> 00:37:31.290 And then there was second randomization
NOTE Confidence: 0.7044647775

00:37:31.290 --> 00:37:34.029 for patients who achieved a CR.
NOTE Confidence: 0.7044647775

00:37:34.030 --> 00:37:38.970 Between R&R squared maintenance.
NOTE Confidence: 0.7044647775

00:37:38.970 --> 00:37:41.196 So I'm not going to go over
NOTE Confidence: 0.7044647775

00:37:41.196 --> 00:37:42.150 these patient characteristics.
NOTE Confidence: 0.7044647775

00:37:42.150 --> 00:37:45.030 They are well balanced in both
NOTE Confidence: 0.7044647775

00:37:45.030 --> 00:37:48.100 the arms and same thing holds true
NOTE Confidence: 0.7044647775

00:37:48.100 --> 00:37:50.700 for the maintenance arm as well.
NOTE Confidence: 0.7044647775

00:37:50.700 --> 00:37:53.610 These were the safety profile differences,
NOTE Confidence: 0.7044647775

00:37:53.610 --> 00:37:56.345 quite significant blood and lymphatic
NOTE Confidence: 0.7044647775

00:37:56.345 --> 00:37:58.533 system disorders were observed
NOTE Confidence: 0.7044647775

00:37:58.533 --> 00:38:02.020 in R-squared versus hour and not
NOTE Confidence: 0.7044647775

00:38:02.020 --> 00:38:05.120 unexpectedly higher grades of neutropenia,

NOTE Confidence: 0.7044647775

00:38:05.120 --> 00:38:07.380 anemia and infections were

NOTE Confidence: 0.7044647775

00:38:07.380 --> 00:38:10.205 observed in the R-squared arm.

NOTE Confidence: 0.7044647775

00:38:10.210 --> 00:38:12.778 Well, these are the PFS and OS curves.

NOTE Confidence: 0.7044647775

00:38:12.780 --> 00:38:15.084 There was no OS difference between the two.

NOTE Confidence: 0.7044647775

00:38:15.090 --> 00:38:18.180 While there was a higher PFS

NOTE Confidence: 0.7044647775

00:38:18.180 --> 00:38:20.730 benefit in the R-squared arm.

NOTE Confidence: 0.7044647775

00:38:20.730 --> 00:38:23.957 What I found most interesting was the

NOTE Confidence: 0.7044647775

00:38:23.957 --> 00:38:27.831 MRD analysis on in on this set of

NOTE Confidence: 0.7044647775

00:38:27.831 --> 00:38:30.226 patients where we found paradoxically

NOTE Confidence: 0.7044647775

00:38:30.230 --> 00:38:35.206 improved PFS in the R-squared arm in MRD

NOTE Confidence: 0.7044647775

00:38:35.206 --> 00:38:37.995 negative patients versus MRD positive.

NOTE Confidence: 0.7044647775

00:38:37.995 --> 00:38:40.570 The difference is quite striking

NOTE Confidence: 0.7044647775

00:38:40.570 --> 00:38:44.089 61% versus 84%.

NOTE Confidence: 0.7044647775

00:38:44.090 --> 00:38:46.450 So the conclusions are,

NOTE Confidence: 0.7044647775

00:38:46.450 --> 00:38:47.630 I think,

NOTE Confidence: 0.7044647775

00:38:47.630 --> 00:38:50.294 mainly that there is an MRD
NOTE Confidence: 0.7044647775

00:38:50.294 --> 00:38:52.653 below the detection threshold of
NOTE Confidence: 0.7044647775

00:38:52.653 --> 00:38:54.649 the currently used technique.
NOTE Confidence: 0.7044647775

00:38:54.650 --> 00:38:55.135 Clearly,
NOTE Confidence: 0.7044647775

00:38:55.135 --> 00:38:57.560 since there was improvement in
NOTE Confidence: 0.7044647775

00:38:57.560 --> 00:38:59.950 the experimental arm which added
NOTE Confidence: 0.7044647775

00:38:59.950 --> 00:39:01.525 in negative patients,
NOTE Confidence: 0.7044647775

00:39:01.525 --> 00:39:05.200 so we have to take murded studies
NOTE Confidence: 0.7044647775

00:39:05.297 --> 00:39:08.561 and you know analyze them carefully
NOTE Confidence: 0.7044647775

00:39:08.561 --> 00:39:11.980 before making any big conclusions.
NOTE Confidence: 0.7044647775

00:39:11.980 --> 00:39:12.224 Lastly,
NOTE Confidence: 0.7044647775

00:39:12.224 --> 00:39:13.932 I would like to show a couple
NOTE Confidence: 0.7044647775

00:39:13.932 --> 00:39:15.410 of slides on to fit the map.
NOTE Confidence: 0.7044647775

00:39:15.410 --> 00:39:17.918 A step up dosing in relapse,
NOTE Confidence: 0.7044647775

00:39:17.920 --> 00:39:19.720 refractory mantle cell lymphoma
NOTE Confidence: 0.7044647775

00:39:19.720 --> 00:39:22.420 who had paid failed priority care

NOTE Confidence: 0.7044647775

00:39:22.495 --> 00:39:25.060 therapy presented by Doctor Phillips.

NOTE Confidence: 0.7044647775

00:39:25.060 --> 00:39:29.148 Blue Phantom AB is a 20CD3 bispecific

NOTE Confidence: 0.7044647775

00:39:29.148 --> 00:39:31.068 antibody engager with two is

NOTE Confidence: 0.7044647775

00:39:31.068 --> 00:39:32.930 21 configuration as shown here.

NOTE Confidence: 0.888712264285714

00:39:35.120 --> 00:39:38.020 This was done in combination

NOTE Confidence: 0.888712264285714

00:39:38.020 --> 00:39:39.180 with obinutuzumab.

NOTE Confidence: 0.888712264285714

00:39:39.180 --> 00:39:42.300 Either invest fixed dosing or step up dosing.

NOTE Confidence: 0.888712264285714

00:39:42.300 --> 00:39:44.253 What I want to draw your attention

NOTE Confidence: 0.888712264285714

00:39:44.253 --> 00:39:45.720 to is most patients.

NOTE Confidence: 0.888712264285714

00:39:45.720 --> 00:39:50.280 69% of patients had relapsed after

NOTE Confidence: 0.888712264285714

00:39:50.280 --> 00:39:53.148 therapy and many of these patients

NOTE Confidence: 0.888712264285714

00:39:53.148 --> 00:39:55.800 were refractory to prior therapy.

NOTE Confidence: 0.888712264285714

00:39:55.800 --> 00:39:58.105 90% of them including refractory

NOTE Confidence: 0.888712264285714

00:39:58.105 --> 00:39:59.949 to first line therapy.

NOTE Confidence: 0.888712264285714

00:39:59.950 --> 00:40:01.190 In half of the patients.

NOTE Confidence: 0.77609080625

00:40:03.470 --> 00:40:05.710 Serious adverse events were
NOTE Confidence: 0.77609080625

00:40:05.710 --> 00:40:09.420 observed in in this small study,
NOTE Confidence: 0.77609080625

00:40:09.420 --> 00:40:12.360 including 62% of patients,
NOTE Confidence: 0.77609080625

00:40:12.360 --> 00:40:15.330 most of them being related to Blue Fit map.
NOTE Confidence: 0.77609080625

00:40:15.330 --> 00:40:17.622 But important to note that no
NOTE Confidence: 0.77609080625

00:40:17.622 --> 00:40:19.915 adverse events leading to treatment
NOTE Confidence: 0.77609080625

00:40:19.915 --> 00:40:21.997 discontinuation were reported.
NOTE Confidence: 0.77609080625

00:40:22.000 --> 00:40:25.846 And these are the adverse events.
NOTE Confidence: 0.77609080625

00:40:25.850 --> 00:40:27.266 Cytokine release syndrome
NOTE Confidence: 0.77609080625

00:40:27.266 --> 00:40:29.626 being the most common one.
NOTE Confidence: 0.77609080625

00:40:29.630 --> 00:40:31.784 This is why I thought of
NOTE Confidence: 0.77609080625

00:40:31.784 --> 00:40:33.220 presenting this trial here.
NOTE Confidence: 0.77609080625

00:40:33.220 --> 00:40:38.292 Very high CR rates and over our
NOTE Confidence: 0.77609080625

00:40:38.292 --> 00:40:42.464 rates 67% in all patients and CR
NOTE Confidence: 0.77609080625

00:40:42.464 --> 00:40:45.668 versus 81% overall response rate,
NOTE Confidence: 0.77609080625

00:40:45.668 --> 00:40:48.276 especially in patients who

NOTE Confidence: 0.77609080625

00:40:48.276 --> 00:40:51.060 have received prior therapy.

NOTE Confidence: 0.77609080625

00:40:51.060 --> 00:40:54.806 So we believe that bytes bytes

NOTE Confidence: 0.77609080625

00:40:54.806 --> 00:40:57.164 specific bispecific T cell engagers are

NOTE Confidence: 0.77609080625

00:40:57.164 --> 00:40:59.729 going to play an important role in.

NOTE Confidence: 0.77609080625

00:40:59.730 --> 00:41:01.814 Refractory mantle cell lymphoma

NOTE Confidence: 0.77609080625

00:41:01.814 --> 00:41:03.377 in the future.

NOTE Confidence: 0.77609080625

00:41:03.380 --> 00:41:05.396 Thank you and I'll pass on

NOTE Confidence: 0.77609080625

00:41:05.396 --> 00:41:06.740 to Doctor Kirschen Sethi,

NOTE Confidence: 0.77609080625

00:41:06.740 --> 00:41:08.665 who will present in Hodgkin

NOTE Confidence: 0.77609080625

00:41:08.665 --> 00:41:10.205 lymphoma and diesel lymphomas.

NOTE Confidence: 0.8504945711111111

00:41:13.710 --> 00:41:15.270 Hi everyone, while I'm

NOTE Confidence: 0.8504945711111111

00:41:15.270 --> 00:41:17.220 trying to share my slides.

NOTE Confidence: 0.8504945711111111

00:41:17.220 --> 00:41:18.977 Thank you so much for joining us.

NOTE Confidence: 0.902381872

00:41:34.590 --> 00:41:36.670 Alright, so I'm going to.

NOTE Confidence: 0.902381872

00:41:36.670 --> 00:41:38.250 I have no relevant disclosures.

NOTE Confidence: 0.902381872

00:41:38.250 --> 00:41:40.966 I'm going to start with Hodgkin lymphoma.

NOTE Confidence: 0.902381872

00:41:40.970 --> 00:41:43.450 My intention is to do a

NOTE Confidence: 0.902381872

00:41:43.450 --> 00:41:46.010 very broad overview of.

NOTE Confidence: 0.902381872

00:41:46.010 --> 00:41:48.002 Where the field is moving and

NOTE Confidence: 0.902381872

00:41:48.002 --> 00:41:49.670 both of these topics are.

NOTE Confidence: 0.902381872

00:41:49.670 --> 00:41:53.828 That is Hodgkin and T cell lymphomas.

NOTE Confidence: 0.902381872

00:41:53.830 --> 00:41:56.170 So first we'll start with some

NOTE Confidence: 0.902381872

00:41:56.170 --> 00:41:57.730 frontline trials in Hodgkin

NOTE Confidence: 0.902381872

00:41:57.800 --> 00:42:00.344 lymphoma and then moving on to

NOTE Confidence: 0.902381872

00:42:00.344 --> 00:42:02.040 some relapsed refractory trials.

NOTE Confidence: 0.902381872

00:42:02.040 --> 00:42:04.144 I think it's just important to note that

NOTE Confidence: 0.902381872

00:42:04.144 --> 00:42:06.204 all of these are basically checkpoint

NOTE Confidence: 0.902381872

00:42:06.204 --> 00:42:10.060 therapy based studies that I had I have.

NOTE Confidence: 0.902381872

00:42:10.060 --> 00:42:11.228 Included here,

NOTE Confidence: 0.902381872

00:42:11.228 --> 00:42:14.148 as you can see here,

NOTE Confidence: 0.902381872

00:42:14.150 --> 00:42:15.794 you know checkpoint in a better

NOTE Confidence: 0.902381872

00:42:15.794 --> 00:42:17.583 therapy is being brought into the

NOTE Confidence: 0.902381872

00:42:17.583 --> 00:42:18.855 frontline in Hodgkin lymphoma.

NOTE Confidence: 0.902381872

00:42:18.860 --> 00:42:22.580 In the in the hope of improving long

NOTE Confidence: 0.902381872

00:42:22.580 --> 00:42:26.027 term outcome while reducing toxicity and

NOTE Confidence: 0.902381872

00:42:26.027 --> 00:42:29.780 then at the same time you we also have.

NOTE Confidence: 0.902381872

00:42:29.780 --> 00:42:32.880 You know, relapse refractory.

NOTE Confidence: 0.902381872

00:42:32.880 --> 00:42:34.996 Specially the population that

NOTE Confidence: 0.902381872

00:42:34.996 --> 00:42:37.112 relapses post autologous stem

NOTE Confidence: 0.902381872

00:42:37.112 --> 00:42:39.936 cell transplant and there is a,

NOTE Confidence: 0.902381872

00:42:39.936 --> 00:42:41.904 uh, a need for.

NOTE Confidence: 0.902381872

00:42:41.910 --> 00:42:43.535 Therapy in patients who fail

NOTE Confidence: 0.902381872

00:42:43.535 --> 00:42:45.686 both been tax map and checkpoint

NOTE Confidence: 0.902381872

00:42:45.686 --> 00:42:47.506 inhibition in that line,

NOTE Confidence: 0.902381872

00:42:47.510 --> 00:42:49.406 and so that's where some of

NOTE Confidence: 0.902381872

00:42:49.406 --> 00:42:51.000 most of these studies are.

NOTE Confidence: 0.696124229166667

00:42:53.210 --> 00:42:55.877 That's the the the therapy they need
NOTE Confidence: 0.696124229166667

00:42:55.877 --> 00:42:58.129 that these studies are addressing.
NOTE Confidence: 0.696124229166667

00:42:58.130 --> 00:43:00.290 So first the frontline of the
NOTE Confidence: 0.696124229166667

00:43:00.290 --> 00:43:02.492 study that I'd like to mention
NOTE Confidence: 0.696124229166667

00:43:02.492 --> 00:43:06.286 is the by Doctor Alan at Emory,
NOTE Confidence: 0.696124229166667

00:43:06.290 --> 00:43:07.880 and this was looking at
NOTE Confidence: 0.696124229166667

00:43:07.880 --> 00:43:08.834 single agent pembrolizumab.
NOTE Confidence: 0.696124229166667

00:43:08.840 --> 00:43:10.848 I've followed by avd.
NOTE Confidence: 0.696124229166667

00:43:10.848 --> 00:43:12.856 For classical Hodgkin lymphoma,
NOTE Confidence: 0.696124229166667

00:43:12.860 --> 00:43:15.216 so this is Brett.
NOTE Confidence: 0.696124229166667

00:43:15.216 --> 00:43:18.161 This particular presentation was an
NOTE Confidence: 0.696124229166667

00:43:18.161 --> 00:43:21.110 update from a prior ASH presentation
NOTE Confidence: 0.696124229166667

00:43:21.110 --> 00:43:23.945 where they had presented the primary
NOTE Confidence: 0.696124229166667

00:43:23.945 --> 00:43:26.375 endpoint that is the complete metabolic
NOTE Confidence: 0.696124229166667

00:43:26.375 --> 00:43:28.154 response rate by pet city initially.
NOTE Confidence: 0.696124229166667

00:43:28.154 --> 00:43:30.458 So the brief background of this

NOTE Confidence: 0.696124229166667
00:43:30.458 --> 00:43:34.130 study was that as we know, 9 feet,
NOTE Confidence: 0.696124229166667
00:43:34.130 --> 00:43:36.745 24.1 amplification is common in
NOTE Confidence: 0.696124229166667
00:43:36.745 --> 00:43:38.837 patients with Hodgkin lymphoma.
NOTE Confidence: 0.696124229166667
00:43:38.840 --> 00:43:42.746 And so this study by design was.
NOTE Confidence: 0.696124229166667
00:43:42.750 --> 00:43:45.342 You had the lead in pembrolizumab
NOTE Confidence: 0.696124229166667
00:43:45.342 --> 00:43:48.118 primarily to be able to get some.
NOTE Confidence: 0.696124229166667
00:43:48.120 --> 00:43:50.685 Correlated data for febrile alone
NOTE Confidence: 0.696124229166667
00:43:50.685 --> 00:43:54.250 in these patients and to be able to.
NOTE Confidence: 0.696124229166667
00:43:54.250 --> 00:43:58.428 Again, see what is it that is
NOTE Confidence: 0.696124229166667
00:43:58.430 --> 00:44:00.554 correlating with both response
NOTE Confidence: 0.696124229166667
00:44:00.554 --> 00:44:03.209 and prognosis in these patients?
NOTE Confidence: 0.696124229166667
00:44:03.210 --> 00:44:05.875 So this particular abstract was
NOTE Confidence: 0.696124229166667
00:44:05.875 --> 00:44:08.007 presenting the secondary endpoints
NOTE Confidence: 0.696124229166667
00:44:08.007 --> 00:44:10.750 of updated PFS and overall survival
NOTE Confidence: 0.696124229166667
00:44:10.750 --> 00:44:13.730 at around the 33 month follow up,
NOTE Confidence: 0.696124229166667

00:44:13.730 --> 00:44:18.020 and then also further correlative studies.
NOTE Confidence: 0.696124229166667

00:44:18.020 --> 00:44:21.422 So this as I mentioned it was
NOTE Confidence: 0.696124229166667

00:44:21.422 --> 00:44:23.549 sequential Pembroke followed by Avd.
NOTE Confidence: 0.696124229166667

00:44:23.550 --> 00:44:28.241 The after the initial PET scan 3 cycles
NOTE Confidence: 0.696124229166667

00:44:28.241 --> 00:44:30.463 of pembrolizumab was were given and
NOTE Confidence: 0.696124229166667

00:44:30.463 --> 00:44:33.210 then the second PET scan was obtained.
NOTE Confidence: 0.696124229166667

00:44:33.210 --> 00:44:34.650 At this point of time,
NOTE Confidence: 0.696124229166667

00:44:34.650 --> 00:44:36.435 the primary endpoint of complete
NOTE Confidence: 0.696124229166667

00:44:36.435 --> 00:44:37.863 of metabolic is complete.
NOTE Confidence: 0.696124229166667

00:44:37.870 --> 00:44:40.250 Metabolic response was assessed
NOTE Confidence: 0.696124229166667

00:44:40.250 --> 00:44:43.792 and then in addition they did.
NOTE Confidence: 0.696124229166667

00:44:43.792 --> 00:44:46.602 Correlative studies that included both
NOTE Confidence: 0.696124229166667

00:44:46.602 --> 00:44:49.617 immunohistochemistry as well as fish 9.
NOTE Confidence: 0.696124229166667

00:44:49.617 --> 00:44:50.778 P, 24.1 alterations.
NOTE Confidence: 0.696124229166667

00:44:50.778 --> 00:44:53.730 Then patients went on to receive a video.
NOTE Confidence: 0.963252371666667

00:44:57.130 --> 00:45:00.638 So as you can see here, the median age.

NOTE Confidence: 0.963252371666667
00:45:00.640 --> 00:45:03.928 For this patient, cohort was 29,
NOTE Confidence: 0.963252371666667
00:45:03.928 --> 00:45:05.868 but they did include patients
NOTE Confidence: 0.963252371666667
00:45:05.868 --> 00:45:08.482 up to 77 years of age and
NOTE Confidence: 0.963252371666667
00:45:08.482 --> 00:45:10.120 about 15% for elderly patients.
NOTE Confidence: 0.72681260375
00:45:12.290 --> 00:45:16.858 They enrolled a total of 30 patients and.
NOTE Confidence: 0.72681260375
00:45:16.860 --> 00:45:19.472 60% were advanced stage
NOTE Confidence: 0.72681260375
00:45:19.472 --> 00:45:23.126 Hodgkin and 40% were early.
NOTE Confidence: 0.72681260375
00:45:23.126 --> 00:45:24.690 Unfavorable Hodgkin.
NOTE Confidence: 0.72681260375
00:45:24.690 --> 00:45:28.190 So on the top right of the
NOTE Confidence: 0.72681260375
00:45:28.190 --> 00:45:30.880 slide you can see that.
NOTE Confidence: 0.72681260375
00:45:30.880 --> 00:45:33.770 The there basically assessment of
NOTE Confidence: 0.72681260375
00:45:33.770 --> 00:45:35.871 the complete metabolic response
NOTE Confidence: 0.72681260375
00:45:35.871 --> 00:45:38.406 after three cycles of pembrolizumab.
NOTE Confidence: 0.72681260375
00:45:38.410 --> 00:45:41.548 They defined a parameter called near
NOTE Confidence: 0.72681260375
00:45:41.548 --> 00:45:43.962 complete medical complete metabolic response,
NOTE Confidence: 0.72681260375

00:45:43.962 --> 00:45:47.373 which was defined as more than 90%
NOTE Confidence: 0.72681260375

00:45:47.373 --> 00:45:50.788 in metabolically active tumor volume,
NOTE Confidence: 0.72681260375

00:45:50.790 --> 00:45:54.185 and they found that nearly that CR,
NOTE Confidence: 0.72681260375

00:45:54.190 --> 00:45:57.319 along with near CR was seen in
NOTE Confidence: 0.72681260375

00:45:57.319 --> 00:45:59.750 about 63% of patients that embryo
NOTE Confidence: 0.72681260375

00:45:59.750 --> 00:46:01.158 alone in the frontline.
NOTE Confidence: 0.788871018333333

00:46:03.510 --> 00:46:05.202 And the remaining patients
NOTE Confidence: 0.788871018333333

00:46:05.202 --> 00:46:06.856 had a partial response.
NOTE Confidence: 0.788871018333333

00:46:06.856 --> 00:46:09.274 In addition, they also looked at.
NOTE Confidence: 0.825995102

00:46:12.090 --> 00:46:14.904 At this time, they reported updated
NOTE Confidence: 0.825995102

00:46:14.904 --> 00:46:17.258 PFS and overall survival data,
NOTE Confidence: 0.825995102

00:46:17.258 --> 00:46:19.648 which showed 100% progression free
NOTE Confidence: 0.825995102

00:46:19.648 --> 00:46:22.658 survival as well as overall survival
NOTE Confidence: 0.825995102

00:46:22.658 --> 00:46:26.498 at a median follow-up of 33 months.
NOTE Confidence: 0.825995102

00:46:26.498 --> 00:46:28.030 In addition, there.
NOTE Confidence: 0.825995102

00:46:28.030 --> 00:46:29.950 This study was very well designed

NOTE Confidence: 0.825995102

00:46:29.950 --> 00:46:32.316 in terms of Correlators after the

NOTE Confidence: 0.825995102

00:46:32.316 --> 00:46:35.592 lead in Pember Lizum app and they

NOTE Confidence: 0.825995102

00:46:35.592 --> 00:46:39.191 noted that alterations of 1924.1,

NOTE Confidence: 0.825995102

00:46:39.191 --> 00:46:41.177 which they defined as either die.

NOTE Confidence: 0.825995102

00:46:41.180 --> 00:46:44.407 So my polysemy copy number gain or

NOTE Confidence: 0.825995102

00:46:44.410 --> 00:46:47.416 amplification was present in one sum,

NOTE Confidence: 0.825995102

00:46:47.420 --> 00:46:50.940 one form or the other in all of the patients.

NOTE Confidence: 0.825995102

00:46:50.940 --> 00:46:52.725 It's 100% of the patients

NOTE Confidence: 0.825995102

00:46:52.725 --> 00:46:54.604 that they had tissue on,

NOTE Confidence: 0.825995102

00:46:54.604 --> 00:46:57.438 which is 28 out of the 30 patients.

NOTE Confidence: 0.825995102

00:46:57.440 --> 00:46:59.470 And.

NOTE Confidence: 0.825995102

00:46:59.470 --> 00:47:02.692 In looking at a more the

NOTE Confidence: 0.825995102

00:47:02.692 --> 00:47:04.303 immunohistochemistry they calculated

NOTE Confidence: 0.825995102

00:47:04.303 --> 00:47:07.081 and age score which was combining

NOTE Confidence: 0.825995102

00:47:07.081 --> 00:47:10.898 the intensity and intensity of PDL 1.

NOTE Confidence: 0.825995102

00:47:10.898 --> 00:47:13.168 Staining along with the percentage
NOTE Confidence: 0.825995102

00:47:13.168 --> 00:47:15.780 of cells that were positive.
NOTE Confidence: 0.825995102

00:47:15.780 --> 00:47:19.835 And they compared both of these to
NOTE Confidence: 0.825995102

00:47:19.835 --> 00:47:21.730 the response to response between
NOTE Confidence: 0.825995102

00:47:21.798 --> 00:47:23.758 responders and non responders.
NOTE Confidence: 0.825995102

00:47:23.760 --> 00:47:25.699 And they did not find any correlation
NOTE Confidence: 0.825995102

00:47:25.699 --> 00:47:28.100 between PDF and pathway markers and response.
NOTE Confidence: 0.62557054

00:47:30.190 --> 00:47:35.198 So in conclusion, this.
NOTE Confidence: 0.62557054

00:47:35.200 --> 00:47:37.770 Was a pretty well tolerated
NOTE Confidence: 0.62557054

00:47:37.770 --> 00:47:39.826 regimen where no additional
NOTE Confidence: 0.62557054

00:47:39.826 --> 00:47:44.110 signal of safety was seen and.
NOTE Confidence: 0.62557054

00:47:44.110 --> 00:47:48.506 Their base they looked at long term
NOTE Confidence: 0.62557054

00:47:48.506 --> 00:47:51.782 into 33 month overall survival at PFS,
NOTE Confidence: 0.62557054

00:47:51.790 --> 00:47:54.078 which was both 100%,
NOTE Confidence: 0.62557054

00:47:54.078 --> 00:47:57.390 so it was fairly effective regimen,
NOTE Confidence: 0.62557054

00:47:57.390 --> 00:48:00.705 and along with that they did not find any

NOTE Confidence: 0.62557054

00:48:00.705 --> 00:48:02.324 correlation between the PD one pathway

NOTE Confidence: 0.62557054

00:48:02.324 --> 00:48:04.088 markers and the depth of response.

NOTE Confidence: 0.62557054

00:48:04.090 --> 00:48:06.230 So they basically they were.

NOTE Confidence: 0.62557054

00:48:06.230 --> 00:48:08.846 They implied that you could see

NOTE Confidence: 0.62557054

00:48:08.846 --> 00:48:11.265 favorable responses and even in patients

NOTE Confidence: 0.62557054

00:48:11.265 --> 00:48:13.700 who had low PD L1 positive ITI.

NOTE Confidence: 0.62557054

00:48:13.700 --> 00:48:16.955 So this combination and are now going

NOTE Confidence: 0.62557054

00:48:16.955 --> 00:48:20.900 to be studied in phase three trial and

NOTE Confidence: 0.62557054

00:48:20.900 --> 00:48:25.780 again one of the active combinations in

NOTE Confidence: 0.62557054

00:48:25.780 --> 00:48:28.340 frontline using checkpoint inhibition.

NOTE Confidence: 0.62557054

00:48:28.340 --> 00:48:30.908 I'm only going to briefly going to go

NOTE Confidence: 0.62557054

00:48:30.908 --> 00:48:33.777 through the concurrent Pembroke and DVD data.

NOTE Confidence: 0.62557054

00:48:33.780 --> 00:48:34.168 Again.

NOTE Confidence: 0.62557054

00:48:34.168 --> 00:48:35.720 This was frontline here.

NOTE Confidence: 0.62557054

00:48:35.720 --> 00:48:38.037 There was no lead in and this

NOTE Confidence: 0.62557054

00:48:38.040 --> 00:48:39.633 this was basically.
NOTE Confidence: 0.62557054

00:48:39.633 --> 00:48:43.350 I bought the drugs were given concurrently
NOTE Confidence: 0.62557054

00:48:43.350 --> 00:48:45.120 and one difference between the prior
NOTE Confidence: 0.62557054

00:48:45.120 --> 00:48:47.233 study and this was that this was
NOTE Confidence: 0.62557054

00:48:47.233 --> 00:48:48.973 primarily a safety signal study that
NOTE Confidence: 0.62557054

00:48:48.973 --> 00:48:51.254 was the primary endpoint and then the
NOTE Confidence: 0.62557054

00:48:51.254 --> 00:48:54.940 secondary endpoint was the CR rate.
NOTE Confidence: 0.62557054

00:48:54.940 --> 00:48:58.028 So in this particular.
NOTE Confidence: 0.62557054

00:48:58.030 --> 00:49:00.258 Study they assess response
NOTE Confidence: 0.62557054

00:49:00.258 --> 00:49:03.043 after two cycles of Pembroke,
NOTE Confidence: 0.62557054

00:49:03.050 --> 00:49:06.200 given concurrently with Avd and
NOTE Confidence: 0.62557054

00:49:06.200 --> 00:49:09.014 then depending upon the stage.
NOTE Confidence: 0.62557054

00:49:09.014 --> 00:49:11.262 Because this study included
NOTE Confidence: 0.62557054

00:49:11.262 --> 00:49:13.566 patients through all stages.
NOTE Confidence: 0.62557054

00:49:13.570 --> 00:49:15.810 If you look at the patient characteristics,
NOTE Confidence: 0.62557054

00:49:15.810 --> 00:49:17.730 it included patients that were

NOTE Confidence: 0.62557054

00:49:17.730 --> 00:49:20.564 stay as as early as stage one

NOTE Confidence: 0.62557054

00:49:20.564 --> 00:49:22.649 to stage through stage four,

NOTE Confidence: 0.62557054

00:49:22.650 --> 00:49:24.960 so the total number of cycles

NOTE Confidence: 0.62557054

00:49:24.960 --> 00:49:28.370 really depend on what the stage was.

NOTE Confidence: 0.62557054

00:49:28.370 --> 00:49:30.020 But since their primary endpoint

NOTE Confidence: 0.62557054

00:49:30.020 --> 00:49:31.670 was safety after two cycles,

NOTE Confidence: 0.62557054

00:49:31.670 --> 00:49:35.012 they and the main secondary endpoint

NOTE Confidence: 0.62557054

00:49:35.012 --> 00:49:39.630 was response after two cycles that.

NOTE Confidence: 0.62557054

00:49:39.630 --> 00:49:41.412 So that was assessed basically regardless

NOTE Confidence: 0.62557054

00:49:41.412 --> 00:49:43.140 of the total number of titles.

NOTE Confidence: 0.841524545714286

00:49:47.660 --> 00:49:50.544 So since the primary endpoint was safety,

NOTE Confidence: 0.841524545714286

00:49:50.550 --> 00:49:54.580 they showed that the main.

NOTE Confidence: 0.841524545714286

00:49:54.580 --> 00:49:56.722 Non habit illogical.

NOTE Confidence: 0.841524545714286

00:49:56.722 --> 00:49:59.611 Side effects that were grade

NOTE Confidence: 0.841524545714286

00:49:59.611 --> 00:50:02.533 grade three or four they were.

NOTE Confidence: 0.841524545714286

00:50:02.540 --> 00:50:05.138 Very minimal and in terms of
NOTE Confidence: 0.841524545714286

00:50:05.138 --> 00:50:06.870 immune related side effects,
NOTE Confidence: 0.841524545714286

00:50:06.870 --> 00:50:11.000 they had grade 3-4 transmitters,
NOTE Confidence: 0.841524545714286

00:50:11.000 --> 00:50:13.220 specifically the the one patient
NOTE Confidence: 0.841524545714286

00:50:13.220 --> 00:50:14.996 with grilled 4 transmitters.
NOTE Confidence: 0.841524545714286

00:50:15.000 --> 00:50:16.875 They had a concurrent use
NOTE Confidence: 0.841524545714286

00:50:16.875 --> 00:50:19.140 of over the counter CBD oil.
NOTE Confidence: 0.841524545714286

00:50:19.140 --> 00:50:22.416 It appears like so they it was.
NOTE Confidence: 0.841524545714286

00:50:22.420 --> 00:50:24.562 They were not sure whether it
NOTE Confidence: 0.841524545714286

00:50:24.562 --> 00:50:26.480 was truly drug related versus
NOTE Confidence: 0.841524545714286

00:50:26.480 --> 00:50:29.480 related to this CBD oil use,
NOTE Confidence: 0.841524545714286

00:50:29.480 --> 00:50:31.880 but and then there were a few patients.
NOTE Confidence: 0.841524545714286

00:50:31.880 --> 00:50:34.150 Three patients with grade 3.
NOTE Confidence: 0.841524545714286

00:50:34.150 --> 00:50:35.742 Transformers and all of
NOTE Confidence: 0.841524545714286

00:50:35.742 --> 00:50:37.334 those cases were reversible,
NOTE Confidence: 0.841524545714286

00:50:37.340 --> 00:50:38.290 so overall,

NOTE Confidence: 0.841524545714286
00:50:38.290 --> 00:50:40.665 this regimen was thought to
NOTE Confidence: 0.841524545714286
00:50:40.665 --> 00:50:42.090 be well tolerated.
NOTE Confidence: 0.753642434615385
00:50:44.740 --> 00:50:47.776 In, when the two when immune
NOTE Confidence: 0.753642434615385
00:50:47.776 --> 00:50:49.294 checkpoint inhibitor and
NOTE Confidence: 0.753642434615385
00:50:49.294 --> 00:50:51.638 chemotherapy was given concurrently.
NOTE Confidence: 0.753642434615385
00:50:51.640 --> 00:50:52.980 Their per two CR rate,
NOTE Confidence: 0.753642434615385
00:50:52.980 --> 00:50:54.360 which was the secondary endpoint,
NOTE Confidence: 0.753642434615385
00:50:54.360 --> 00:50:58.210 was 66% in all patients.
NOTE Confidence: 0.753642434615385
00:50:58.210 --> 00:51:00.510 The overall response rate was 100%.
NOTE Confidence: 0.5935753875
00:51:02.850 --> 00:51:05.790 They reported a median follow at a
NOTE Confidence: 0.5935753875
00:51:05.790 --> 00:51:07.824 median follow-up of 16.2 months.
NOTE Confidence: 0.5935753875
00:51:07.824 --> 00:51:11.100 They reported a PFS in overall survival of.
NOTE Confidence: 0.62452483
00:51:14.000 --> 00:51:16.755 So. Basically,
NOTE Confidence: 0.62452483
00:51:16.755 --> 00:51:20.145 the median was not reached and.
NOTE Confidence: 0.62452483
00:51:20.150 --> 00:51:22.775 The one year old also I was
NOTE Confidence: 0.62452483

00:51:22.775 --> 00:51:26.660 100% one year, PFS was 96%.
NOTE Confidence: 0.62452483

00:51:26.660 --> 00:51:29.040 I think one important thing that is
NOTE Confidence: 0.62452483

00:51:29.040 --> 00:51:31.386 important that is keep to both of
NOTE Confidence: 0.62452483

00:51:31.386 --> 00:51:33.600 these studies in the frontline is that
NOTE Confidence: 0.62452483

00:51:33.600 --> 00:51:36.648 immune checkpoint in a better use.
NOTE Confidence: 0.62452483

00:51:36.650 --> 00:51:39.359 Stand result in.
NOTE Confidence: 0.62452483

00:51:39.360 --> 00:51:42.306 So PET scans cannot are probably
NOTE Confidence: 0.62452483

00:51:42.306 --> 00:51:45.498 not as it's not as straightforward.
NOTE Confidence: 0.62452483

00:51:45.498 --> 00:51:49.050 How do you interpret PET scans in the
NOTE Confidence: 0.62452483

00:51:49.050 --> 00:51:51.097 setting of immune checkpoint inhibitors?
NOTE Confidence: 0.62452483

00:51:51.097 --> 00:51:54.792 And so it would make sense to look
NOTE Confidence: 0.62452483

00:51:54.792 --> 00:51:57.684 at novel things like there is.
NOTE Confidence: 0.62452483

00:51:57.690 --> 00:52:00.476 There are the lyric criteria for pet
NOTE Confidence: 0.62452483

00:52:00.476 --> 00:52:02.870 city in patients with immune checkpoint
NOTE Confidence: 0.62452483

00:52:02.870 --> 00:52:07.520 in a better doctor Alan study looked at.
NOTE Confidence: 0.62452483

00:52:07.520 --> 00:52:09.870 The total metabolic tumor volume

NOTE Confidence: 0.62452483

00:52:09.870 --> 00:52:12.220 in this particular study looked

NOTE Confidence: 0.62452483

00:52:12.296 --> 00:52:15.226 at circulating tumor DNA and the

NOTE Confidence: 0.62452483

00:52:15.226 --> 00:52:17.917 reported cases where the circulating

NOTE Confidence: 0.62452483

00:52:17.917 --> 00:52:20.059 tumor DNA was both more sensitive

NOTE Confidence: 0.62452483

00:52:20.059 --> 00:52:21.823 and specific measure of residual

NOTE Confidence: 0.62452483

00:52:21.823 --> 00:52:23.408 disease rather than pet city.

NOTE Confidence: 0.8953847

00:52:25.690 --> 00:52:29.302 So. In conclusion, this was

NOTE Confidence: 0.8953847

00:52:29.302 --> 00:52:31.622 a safe and effective regimen,

NOTE Confidence: 0.8953847

00:52:31.622 --> 00:52:35.190 again given in concurrently in the frontline,

NOTE Confidence: 0.8953847

00:52:35.190 --> 00:52:39.530 and again one of the ways that we we see

NOTE Confidence: 0.8953847

00:52:39.530 --> 00:52:41.862 checkpoint inhibition being incorporated

NOTE Confidence: 0.8953847

00:52:41.862 --> 00:52:44.777 into the frontline and Hodgkin.

NOTE Confidence: 0.8953847

00:52:44.780 --> 00:52:48.032 OK, so I'm going to quickly go through

NOTE Confidence: 0.8953847

00:52:48.032 --> 00:52:49.802 three relapse or practice studies

NOTE Confidence: 0.8953847

00:52:49.802 --> 00:52:51.838 that are looking at checkpoint

NOTE Confidence: 0.8953847

00:52:51.838 --> 00:52:54.590 inhibition combinations in relapsed
NOTE Confidence: 0.8953847

00:52:54.590 --> 00:52:56.654 refractory Hodgkin lymphoma.
NOTE Confidence: 0.8953847

00:52:56.660 --> 00:52:59.040 The 1st of this is using drugs.
NOTE Confidence: 0.8953847

00:52:59.040 --> 00:53:01.434 The Jack 2 inhibitor and this is
NOTE Confidence: 0.8953847

00:53:01.434 --> 00:53:03.979 based on the rationale that nine
NOTE Confidence: 0.8953847

00:53:03.980 --> 00:53:07.069 P 24.1 amplification results in
NOTE Confidence: 0.8953847

00:53:07.069 --> 00:53:10.450 amplification not only of the PDL 1
NOTE Confidence: 0.8953847

00:53:10.539 --> 00:53:15.340 PDL 2 pathway but also of Jack 2. And.
NOTE Confidence: 0.8953847

00:53:15.340 --> 00:53:17.475 So that was part of the rationale,
NOTE Confidence: 0.8953847

00:53:17.480 --> 00:53:22.112 and so they used a combination
NOTE Confidence: 0.8953847

00:53:22.112 --> 00:53:24.821 of nivolumab with ruxolitinib and
NOTE Confidence: 0.8953847

00:53:24.821 --> 00:53:27.756 they did a 3 doors, tested 3 doors,
NOTE Confidence: 0.8953847

00:53:27.756 --> 00:53:29.084 levels of regulator there.
NOTE Confidence: 0.832469206666667

00:53:31.820 --> 00:53:34.160 Again, this was the patient population.
NOTE Confidence: 0.832469206666667

00:53:34.160 --> 00:53:35.608 Here was checkpoint inhibitor
NOTE Confidence: 0.832469206666667

00:53:35.608 --> 00:53:37.780 refractory so that the patient had

NOTE Confidence: 0.832469206666667
00:53:37.843 --> 00:53:39.625 already progressed on a checkpoint in
NOTE Confidence: 0.832469206666667
00:53:39.625 --> 00:53:41.889 a bit or single agent therapy before.
NOTE Confidence: 0.84419361
00:53:43.980 --> 00:53:46.080 So the median age of all
NOTE Confidence: 0.84419361
00:53:46.080 --> 00:53:48.409 patients with 38 years and.
NOTE Confidence: 0.91491385
00:53:50.470 --> 00:53:54.270 32% of the patients had had a prior
NOTE Confidence: 0.91491385
00:53:54.270 --> 00:53:55.958 autologous stem cell transplant.
NOTE Confidence: 0.61630088
00:53:58.050 --> 00:54:02.418 So here they saw they reported.
NOTE Confidence: 0.61630088
00:54:02.420 --> 00:54:05.140 Overall response rate of
NOTE Confidence: 0.61630088
00:54:05.140 --> 00:54:07.750 48% and the CR rate of 24%.
NOTE Confidence: 0.836803799166667
00:54:11.480 --> 00:54:13.730 The total duration of response
NOTE Confidence: 0.836803799166667
00:54:13.730 --> 00:54:16.939 you can see here that there were
NOTE Confidence: 0.836803799166667
00:54:16.940 --> 00:54:20.130 several patients that were still.
NOTE Confidence: 0.836803799166667
00:54:20.130 --> 00:54:22.478 Had continued response especially.
NOTE Confidence: 0.880154156666667
00:54:25.990 --> 00:54:28.936 So especially those who had complete
NOTE Confidence: 0.880154156666667
00:54:28.936 --> 00:54:31.240 response with this combination.
NOTE Confidence: 0.68455123

00:54:44.840 --> 00:54:48.390 Sorry so. As you can see here,
NOTE Confidence: 0.68455123

00:54:48.390 --> 00:54:50.532 the they reported the PFS and
NOTE Confidence: 0.68455123

00:54:50.532 --> 00:54:52.570 OS said two years it was,
NOTE Confidence: 0.68455123

00:54:52.570 --> 00:54:56.964 which was were 46% and 87% respectively.
NOTE Confidence: 0.68455123

00:54:56.964 --> 00:54:59.799 In this multiple refractory population.
NOTE Confidence: 0.77482122875

00:55:03.190 --> 00:55:06.030 Most side effects were grade one and two,
NOTE Confidence: 0.77482122875

00:55:06.030 --> 00:55:08.050 and primarily consisted of him,
NOTE Confidence: 0.77482122875

00:55:08.050 --> 00:55:08.923 hematological side effects
NOTE Confidence: 0.77482122875

00:55:08.923 --> 00:55:10.669 as well as GI side effects.
NOTE Confidence: 0.791328805

00:55:13.400 --> 00:55:14.830 And the immune related side
NOTE Confidence: 0.791328805

00:55:14.830 --> 00:55:16.260 effects that were seen were
NOTE Confidence: 0.791328805

00:55:16.320 --> 00:55:18.040 mostly hepatitis and pneumonitis,
NOTE Confidence: 0.791328805

00:55:18.040 --> 00:55:20.740 and all these were reversible.
NOTE Confidence: 0.791328805

00:55:20.740 --> 00:55:23.170 So in the correlative studies,
NOTE Confidence: 0.791328805

00:55:23.170 --> 00:55:26.334 they looked at MD after insulating them.
NOTE Confidence: 0.791328805

00:55:26.340 --> 00:55:28.330 And. They found that there

NOTE Confidence: 0.791328805

00:55:28.330 --> 00:55:29.922 was decreased expression of.

NOTE Confidence: 0.837236971666667

00:55:32.310 --> 00:55:35.916 With the use of this combination.

NOTE Confidence: 0.837236971666667

00:55:35.920 --> 00:55:40.610 So overall this was again found to be a safe.

NOTE Confidence: 0.837236971666667

00:55:40.610 --> 00:55:43.826 Combination in multiplicity refractory

NOTE Confidence: 0.837236971666667

00:55:43.826 --> 00:55:46.310 population including basically all patients

NOTE Confidence: 0.837236971666667

00:55:46.310 --> 00:55:48.830 were checkpoint in a better refractory.

NOTE Confidence: 0.837236971666667

00:55:48.830 --> 00:55:51.049 So I'm going to pause here because

NOTE Confidence: 0.837236971666667

00:55:51.050 --> 00:55:53.510 in the interest of time. And.

NOTE Confidence: 0.806466

00:56:04.870 --> 00:56:06.396 Hi, we're coming up to

NOTE Confidence: 0.806466

00:56:06.396 --> 00:56:07.530 the hour and I know people

NOTE Confidence: 0.785555735074074

00:56:07.573 --> 00:56:09.099 want to use their one o'clock to

NOTE Confidence: 0.785555735074074

00:56:09.099 --> 00:56:10.617 perhaps get outside and do some of

NOTE Confidence: 0.785555735074074

00:56:10.617 --> 00:56:12.823 those nice weather. So there's two.

NOTE Confidence: 0.785555735074074

00:56:12.823 --> 00:56:16.009 I think questions that I have.

NOTE Confidence: 0.785555735074074

00:56:16.010 --> 00:56:17.598 Induction appreciate the same

NOTE Confidence: 0.785555735074074

00:56:17.598 --> 00:56:20.690 one I had which was to Torshin
NOTE Confidence: 0.785555735074074

00:56:20.690 --> 00:56:23.440 in terms of frontline Hodgkin.
NOTE Confidence: 0.785555735074074

00:56:23.440 --> 00:56:25.695 You know PFS ruling overall
NOTE Confidence: 0.785555735074074

00:56:25.695 --> 00:56:27.048 survival for that.
NOTE Confidence: 0.785555735074074

00:56:27.050 --> 00:56:29.815 That one analysis out of Emory shows
NOTE Confidence: 0.785555735074074

00:56:29.815 --> 00:56:32.390 really great with Checkpoint ABA VD,
NOTE Confidence: 0.785555735074074

00:56:32.390 --> 00:56:34.326 but we also have good data on BVD.
NOTE Confidence: 0.785555735074074

00:56:34.330 --> 00:56:36.724 How do how do you think we move forward?
NOTE Confidence: 0.785555735074074

00:56:36.730 --> 00:56:38.935 Do we have a study for that?
NOTE Confidence: 0.785555735074074

00:56:38.940 --> 00:56:40.446 Where are we in terms of
NOTE Confidence: 0.785555735074074

00:56:40.446 --> 00:56:41.199 addressing that question?
NOTE Confidence: 0.805202502857143

00:56:42.330 --> 00:56:45.977 So I believe that there is a.
NOTE Confidence: 0.805202502857143

00:56:45.980 --> 00:56:48.654 There is a frontline study that is
NOTE Confidence: 0.805202502857143

00:56:48.654 --> 00:56:50.504 looking at the comparison between those
NOTE Confidence: 0.805202502857143

00:56:50.504 --> 00:56:52.600 two that can help answer that question,
NOTE Confidence: 0.805202502857143

00:56:52.600 --> 00:56:56.332 but at this point it seems like so as far

NOTE Confidence: 0.805202502857143
00:56:56.332 --> 00:56:57.676 as this particular study was concerned,
NOTE Confidence: 0.805202502857143
00:56:57.680 --> 00:56:59.784 Pembroke followed by it
NOTE Confidence: 0.805202502857143
00:56:59.784 --> 00:57:01.522 did include bulky patients.
NOTE Confidence: 0.805202502857143
00:57:01.522 --> 00:57:03.909 What they found was that most of
NOTE Confidence: 0.805202502857143
00:57:03.909 --> 00:57:06.157 the patients were bulky disease.
NOTE Confidence: 0.805202502857143
00:57:06.160 --> 00:57:09.065 After three cycles of Femoro alone they
NOTE Confidence: 0.805202502857143
00:57:09.065 --> 00:57:11.340 had a near complete metabolic response,
NOTE Confidence: 0.805202502857143
00:57:11.340 --> 00:57:13.320 not necessarily complete metabolic response.
NOTE Confidence: 0.805202502857143
00:57:13.320 --> 00:57:15.504 That was kind of one of the differentiating
NOTE Confidence: 0.805202502857143
00:57:15.504 --> 00:57:17.198 features in that particular study.
NOTE Confidence: 0.805202502857143
00:57:17.200 --> 00:57:18.140 But at the same time,
NOTE Confidence: 0.805202502857143
00:57:18.140 --> 00:57:19.470 when it comes to immunotherapy,
NOTE Confidence: 0.805202502857143
00:57:19.470 --> 00:57:22.222 it's very hard to interpret a lot
NOTE Confidence: 0.805202502857143
00:57:22.222 --> 00:57:24.046 of the patients, like for example.
NOTE Confidence: 0.805202502857143
00:57:24.046 --> 00:57:25.356 Even in the second study,
NOTE Confidence: 0.805202502857143

00:57:25.360 --> 00:57:28.090 the pet 2 positivity did not
NOTE Confidence: 0.805202502857143

00:57:28.090 --> 00:57:29.910 correlate with early relapse.
NOTE Confidence: 0.805202502857143

00:57:29.910 --> 00:57:31.982 So the it's not the same as what
NOTE Confidence: 0.805202502857143

00:57:31.982 --> 00:57:34.221 we see with non immuno therapeutic
NOTE Confidence: 0.805202502857143

00:57:34.221 --> 00:57:36.281 agents like you can sometimes
NOTE Confidence: 0.805202502857143

00:57:36.281 --> 00:57:38.913 have long term responders even if
NOTE Confidence: 0.805202502857143

00:57:38.913 --> 00:57:40.629 they have initial positivity.
NOTE Confidence: 0.805202502857143

00:57:40.630 --> 00:57:40.880 So
NOTE Confidence: 0.825018097272727

00:57:41.400 --> 00:57:43.269 and then I guess the question is
NOTE Confidence: 0.825018097272727

00:57:43.269 --> 00:57:44.680 is sequential versus concurrent.
NOTE Confidence: 0.825018097272727

00:57:44.680 --> 00:57:47.056 Do you think we need a trial randomized
NOTE Confidence: 0.825018097272727

00:57:47.056 --> 00:57:49.323 trial to really address the the
NOTE Confidence: 0.825018097272727

00:57:49.323 --> 00:57:51.735 appropriate timing of checkpoint with avd?
NOTE Confidence: 0.825654972727273

00:57:53.160 --> 00:57:54.252 In the second study,
NOTE Confidence: 0.825654972727273

00:57:54.252 --> 00:57:56.240 I think the first study was more.
NOTE Confidence: 0.825654972727273

00:57:56.240 --> 00:57:59.000 The design was more to understand.

NOTE Confidence: 0.825654972727273

00:57:59.000 --> 00:58:01.232 It was a few years it was started a

NOTE Confidence: 0.825654972727273

00:58:01.232 --> 00:58:03.604 few years ago where we didn't know a

NOTE Confidence: 0.825654972727273

00:58:03.604 --> 00:58:05.537 lot about the correlated correlations

NOTE Confidence: 0.825654972727273

00:58:05.537 --> 00:58:07.619 for this particular for Pember alone

NOTE Confidence: 0.825654972727273

00:58:07.619 --> 00:58:09.609 and the efficacy of Pembroke loan,

NOTE Confidence: 0.825654972727273

00:58:09.610 --> 00:58:11.644 and that was the reason to do the lead

NOTE Confidence: 0.825654972727273

00:58:11.644 --> 00:58:14.170 in rather than the safety measure,

NOTE Confidence: 0.825654972727273

00:58:14.170 --> 00:58:15.634 since the second study is already

NOTE Confidence: 0.825654972727273

00:58:15.634 --> 00:58:16.790 telling us that there is,

NOTE Confidence: 0.825654972727273

00:58:16.790 --> 00:58:18.470 it's safe to do the combination.

NOTE Confidence: 0.825654972727273

00:58:18.470 --> 00:58:21.470 I feel like similar to what we do with BV,

NOTE Confidence: 0.825654972727273

00:58:21.470 --> 00:58:24.914 like AVD versus BB followed by avd.

NOTE Confidence: 0.825654972727273

00:58:24.920 --> 00:58:27.640 I feel like both of those can be

NOTE Confidence: 0.825654972727273

00:58:27.640 --> 00:58:29.590 reasonable options, it seems like.

NOTE Confidence: 0.876679872631579

00:58:30.610 --> 00:58:31.865 That's helpful, thank you and

NOTE Confidence: 0.876679872631579

00:58:31.865 --> 00:58:33.615 then the one thought I had before
NOTE Confidence: 0.876679872631579

00:58:33.615 --> 00:58:35.155 we open it up to the audience.
NOTE Confidence: 0.876679872631579

00:58:35.160 --> 00:58:36.680 If there's questions, please,
NOTE Confidence: 0.876679872631579

00:58:36.680 --> 00:58:39.386 please send them in was to Doctor
NOTE Confidence: 0.876679872631579

00:58:39.386 --> 00:58:41.266 Kathari in terms of the long
NOTE Confidence: 0.876679872631579

00:58:41.266 --> 00:58:42.664 term data from Nordic and and
NOTE Confidence: 0.876679872631579

00:58:42.664 --> 00:58:44.495 the study that you presented is
NOTE Confidence: 0.876679872631579

00:58:44.495 --> 00:58:45.807 anthracycline followed by hydac.
NOTE Confidence: 0.876679872631579

00:58:45.810 --> 00:58:48.490 Do you do that or do you use
NOTE Confidence: 0.876679872631579

00:58:48.490 --> 00:58:50.330 bendamustine with your induction?
NOTE Confidence: 0.876679872631579

00:58:50.330 --> 00:58:50.930 You know how do?
NOTE Confidence: 0.876679872631579

00:58:50.930 --> 00:58:52.210 How do you put that all together?
NOTE Confidence: 0.915571771428571

00:58:53.120 --> 00:58:56.246 Yeah, so there are multiple backbones
NOTE Confidence: 0.915571771428571

00:58:56.246 --> 00:58:58.306 that that have been studied,
NOTE Confidence: 0.915571771428571

00:58:58.306 --> 00:59:01.791 but I must admit that the most studied
NOTE Confidence: 0.915571771428571

00:59:01.791 --> 00:59:03.900 regimen, and now with this data,

NOTE Confidence: 0.915571771428571
00:59:03.900 --> 00:59:06.216 especially with you know high risk
NOTE Confidence: 0.915571771428571
00:59:06.216 --> 00:59:08.556 patients having a survival benefit would
NOTE Confidence: 0.915571771428571
00:59:08.556 --> 00:59:11.300 be our chop alternating with our dehab.
NOTE Confidence: 0.915571771428571
00:59:11.300 --> 00:59:13.828 But you know there is a Nordic regimen
NOTE Confidence: 0.915571771428571
00:59:13.828 --> 00:59:16.061 where you alternate art shop with
NOTE Confidence: 0.915571771428571
00:59:16.061 --> 00:59:18.684 hydro cytarabine and then you have a
NOTE Confidence: 0.915571771428571
00:59:18.684 --> 00:59:20.997 you know sort of more of a US regimen
NOTE Confidence: 0.915571771428571
00:59:21.000 --> 00:59:23.460 of Arminda alternating with our site.
NOTE Confidence: 0.915571771428571
00:59:23.460 --> 00:59:25.938 And again, these are all high doses.
NOTE Confidence: 0.915571771428571
00:59:25.940 --> 00:59:29.940 These macaroons have been studied
NOTE Confidence: 0.915571771428571
00:59:29.940 --> 00:59:31.404 and compared with each other but
NOTE Confidence: 0.915571771428571
00:59:31.404 --> 00:59:32.940 without the site are being part.
NOTE Confidence: 0.915571771428571
00:59:32.940 --> 00:59:33.885 So, for example,
NOTE Confidence: 0.915571771428571
00:59:33.885 --> 00:59:36.090 our chop was compared with our vendor.
NOTE Confidence: 0.915571771428571
00:59:36.090 --> 00:59:38.346 So we are extrapolating that you
NOTE Confidence: 0.915571771428571

00:59:38.346 --> 00:59:40.651 know our Brenda is better than
NOTE Confidence: 0.915571771428571

00:59:40.651 --> 00:59:43.178 our top end would be better even
NOTE Confidence: 0.915571771428571

00:59:43.178 --> 00:59:45.540 when combined with a high dose.
NOTE Confidence: 0.915571771428571

00:59:45.540 --> 00:59:47.570 Of course there are some early stage,
NOTE Confidence: 0.915571771428571

00:59:47.570 --> 00:59:48.478 you know,
NOTE Confidence: 0.915571771428571

00:59:48.478 --> 00:59:50.822 small patient series of prospective
NOTE Confidence: 0.915571771428571

00:59:50.822 --> 00:59:54.259 trials of doing of using our Bender
NOTE Confidence: 0.915571771428571

00:59:54.259 --> 00:59:56.729 alternative with our high dose side.
NOTE Confidence: 0.915571771428571

00:59:56.730 --> 00:59:59.770 So what all to to answer your question,
NOTE Confidence: 0.915571771428571

00:59:59.770 --> 01:00:01.398 there are multiple possibilities
NOTE Confidence: 0.915571771428571

01:00:01.398 --> 01:00:03.433 in frontline mantle cell lymphoma
NOTE Confidence: 0.915571771428571

01:00:03.433 --> 01:00:05.201 and we really haven't established
NOTE Confidence: 0.915571771428571

01:00:05.201 --> 01:00:07.831 1 standard of care like we have in
NOTE Confidence: 0.915571771428571

01:00:07.831 --> 01:00:09.742 diffuse large B cell lymphoma and
NOTE Confidence: 0.915571771428571

01:00:09.742 --> 01:00:12.346 that's something it remains still a bit
NOTE Confidence: 0.915571771428571

01:00:12.346 --> 01:00:15.026 elusive as to what will we'll all use,

NOTE Confidence: 0.915571771428571
01:00:15.030 --> 01:00:15.807 but you know,
NOTE Confidence: 0.915571771428571
01:00:15.807 --> 01:00:17.993 I think it's it's a good problem to
NOTE Confidence: 0.915571771428571
01:00:17.993 --> 01:00:20.163 have where you know you can really
NOTE Confidence: 0.915571771428571
01:00:20.163 --> 01:00:22.029 customize therapy based on the patient,
NOTE Confidence: 0.915571771428571
01:00:22.030 --> 01:00:26.610 comorbidities and age and stratification.
NOTE Confidence: 0.915571771428571
01:00:26.610 --> 01:00:26.860 Thank
NOTE Confidence: 0.818028969411765
01:00:26.870 --> 01:00:29.040 you why we're over the hour and I want to
NOTE Confidence: 0.818028969411765
01:00:29.095 --> 01:00:31.314 thank all the attendees for joining today.
NOTE Confidence: 0.818028969411765
01:00:31.320 --> 01:00:33.448 Feel free to email each of us if
NOTE Confidence: 0.818028969411765
01:00:33.448 --> 01:00:35.643 you have questions about specific
NOTE Confidence: 0.818028969411765
01:00:35.643 --> 01:00:37.630 presentations we you know went over
NOTE Confidence: 0.818028969411765
01:00:37.630 --> 01:00:39.010 today and how we interpret that
NOTE Confidence: 0.818028969411765
01:00:39.060 --> 01:00:40.578 and how we approach our patients.
NOTE Confidence: 0.818028969411765
01:00:40.580 --> 01:00:42.980 We'd be happy to to engage over that,
NOTE Confidence: 0.818028969411765
01:00:42.980 --> 01:00:45.996 but enjoy your Friday and thanks for joining.